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ABSTRACT OF DISSERTATION

ELUCIDATING THE MECHANISM OF LIPL: A NON-HEME FE(II), α -KETOGLUTARATE: URIDINE5’-MONOPHOSPHATE DIOXYGENASE
Several nucleoside natural product antibiotics from Streptomyces sp. and actinomycetes
have recently been shown to target bacterial peptidoglycan cell wall biosynthesis by
inhibiting the bacterial translocase I (MraY). The biosynthetic gene clusters for A-90289,
liposidomycins and caprazamycins revealed a protein with sequence similarity to proteins
annotated as α-KG:taurine dioxygenases (TauD). This enzyme (LipL) is a mononuclear,
non-heme, Fe(II) dependent α-keto glutarate (α-KG) :uridine monophosphate (UMP)
dioxygenase responsible for the net dephosphorylation and two electron oxidation of
UMP to uridine-5’-aldehyde. The postulated reaction coordinates involving the activation
of the C-5’ center in UMP and the corresponding formation of uridine-5’-aldehyde are
modeled on extensive spectroscopic and structural characterizations of TauD. In this
dissertation, the postulated radical mechanism for LipL involving the formation of an
unstable hydroxylated intermediate is investigated via the characterization of a key
product obtained from the reaction of LipL (and its homolog Cpr19) with a synthetically
modified surrogate substrate where the bridging phosphoester oxygen in UMP is replaced
with a 5’ C-P bond. We further validate our hypothesis by analyzing the reactions of both
LipL and Cpr19 with specifically 2H1 – labeled UMP substrate and confirming the expected
products via mass spectrometry. In addition, we explore substrate promiscuity of the
enzymes and utilize a set of site specific mutants of Cpr19 as means of gaining better
insight into the active site residues. Predictive models for Cpr19 and LipL structures are
developed by the combination of experimental results and chemical logic.
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Chapter one: Introduction and Background
1.1.

Natural Products – Significance

Natural products and their derivatives have historically been an invaluable source for the
discovery of novel therapeutics[1]. When applied to drug discovery prior to the advent of
high-throughput screening and the post-genomic era, more than 80% of drugs were
either natural product derived or their semisynthetic versions [2]. In the last ~30 years,
amongst all clinically approved drugs, almost half of the small-molecule new chemical
entities introduced were either natural products, semi-synthetic natural product
analogues or synthetic compounds based on natural products [1]. Even in the context of
current therapeutics, the primary reasons why natural products continue to be important
sources are: a) most of the currently available classes of drugs either contain natural
products or have these as original leads, i.e. there are no known synthetic substitutes for
these complex molecules [3] b) they continue to inspire synthetic, semisynthetic, and
chemo-enzymatic efforts to replicate and diversify complex functional scaffolds [4], c)
they are invaluable tools for deciphering complex metabolic pathways and the associated
unique chemical machineries [5], and d) there is still immense potential for the discovery
of novel therapeutics from unexplored sources [6, 7]. The use of natural products as
sources of therapeutics have conferred unparalleled benefits to mankind, by significantly
increasing the average lifespan of the population, nearly eliminating some infectious
diseases and by exerting control over several neoplastic and viral diseases [8]. As such,
natural products also continue to represent a significant share of the current drug market
[9].
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Despite their historical importance, natural product discovery has been subjected to a
slow decline over the last two decades prompted by a number of scientific and economic
challenges [8] calling into question why natural products still matter in the
pharmaceutical landscape. The increasing resistance to antibiotics, coupled with
decreased efficiency in research, failure in the productivity of classical screening methods,
and decreasing profits to pharmaceutical companies due to regulatory obstacles and
increasing research expenses, have cumulatively contributed to a shift in the research
paradigm [10, 11]. Whilst most large pharma have shifted their research efforts from
natural products discovery to the more profitable drug candidates meant to treat chronic
diseases, research efforts in this field have greatly increased in academia and specialized
pharmaceutical/biotechnological companies with renewed approaches to improved
screening and greater emphasis on developing them to front-line drug candidates [12,
13]. As a result, emerging trends in addition to unrealized expectations from current
research and development strategies are prompting a renewed interest in natural
products as a source of biochemical diversity and lead generation.

1.2.

Need for new antibiotics

Every antibiotic that is introduced for clinical use has a limited shelf life, due to innate or
acquired mechanisms of resistance present in all bacteria. Consequently, the need for
new antibacterial drugs for clinical use is a constant one [14]. Resistance has developed
to all main classes of antibiotics, both natural and synthetic, varying in timeline between

2

different classes of drugs after their first clinical use, and many infectious diseases have
emerged and reemerged worldwide with changes in environmental parameters as well
as with migration in populations [15]. Overuse is a primary driver of antibiotic resistance,
but it is not just in humans – “nontherapeutic” treatment of farm animals and livestock
with low doses of these drugs to promote growth and prevent diseases has also been
criticized as a controversial practice that can potentially introduce antibiotic-resistant
bacteria into the human food supply [16].

Pathogens that are resistant to multiple drugs continue to emerge around the globe,
leading to the ongoing, cyclical need for innovation to combat infectious diseases caused
by multiple drug resistant (MDR) pathogens [17]. According to the Centers for Disease
Control and Prevention’s 2013 Threat Report [18] approximately 23,000 people are killed
each year by infectious diseases in the United States alone. Many more die from
complications from other conditions (patients undergoing chemotherapy, dialysis for
renal failure, surgery, organ transplantation, etc.) exacerbated by infections from
resistant pathogens. The CDC Report estimates an annual expenditure of more than $20
billion arising from these maladies. Of these, almost 11,000 deaths were from methicillinresistant Staphylococcus aureus (MRSA) infections in the United States, while other
diseases like multidrug-resistant and extensively drug-resistant tuberculosis (MDR and
XDR TB) are an increasing threat outside of the United States. In 2012, there were 8.6
million new TB cases globally with a reported 1.3 million deaths, and of them, an
estimated 450,000 people were reported to have acquired MDR-TB [19].
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These statistics are grim, and they are made even more so by the fact that in the last 45
years only five new classes of FDA-approved antibiotics have been introduced to the
market [12, 17, 20]. The dramatic decreases in FDA-approved systemic antibiotics, caused
in part to due to bacterial resistance, regulatory disincentives, and a big innovation gap
has led us to an age where no new molecular entities are currently in phase III [20]. To
revitalize the discovery of new antibiotics is imperative, and the issues associated with
drug resistances and the current drug pipeline means that new compounds with novel
modes of action and/or new targets are of great importance in the continued fight against
infectious diseases.

While traditional antibiotic discovery has been based on cell-growth inhibition assays
followed by identification of the targets, contemporary drug discovery is based in large
part on the screening of small molecules for their ability to bind or otherwise inhibit
specific macromolecular targets [1]. Historically, targets for antibiotic action have been
classified into four major groups: bacterial cell wall biosynthesis, protein biosynthesis
(translation), DNA replication and storage, and folate coenzyme biosynthesis [15].
Research in our lab has been focused on the discovery and identification of potential
inhibitors to a target enzyme via activity-based high throughput enzyme assays, more
specifically, inhibitors to the enzyme bacterial translocase I, a key enzyme that
participates in the biosynthesis of the peptidoglycan cell wall biosynthesis in bacteria. The
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overarching goal of our research is to investigate the biosynthetic pathway of these new
classes of inhibitors/antibiotics focusing on the combined chemical logic and enzymatic
machineries involved.

1.3.

Biosynthesis of the peptidoglycan cell wall

Peptidoglycan is the primary polymeric constituent of bacterial cell walls and is essential
for the survival of all bacteria [21]. The backbone of peptidoglycan consists of an
alternating β-1,4-linked glycan composed of N-acetylglucosamine (GlcNAc) and Nacetylmuramic acid (MurNAc) (Figure 1.3.1). A short polypeptide of five amino acids is
attached to the 3-position of the MurNAc sugar, which allows the cross linking between
the 3-amino acid (lysine or D-aminopimelate) and the 4/5 peptide bond of another
polymeric unit. These crosslinks provide the structural integrity that allows the cell wall
to withstand the osmotic pressure of the cytoplasm. The assembly of the cell wall and
peptidoglycan biosynthesis is a complex process that begins at the cytoplasmic side of the
cell membrane. The entire assembly can be broken down into three distinct stages: 1)
polymerization of the disaccharides and attachment with the polypeptide chains, 2)
initiation of the lipid linked cycle wherein the sugar activated hydrophilic precursor is
attached to a lipid carrier and consequently flipped outwards of the membrane, and 3)
the cross-linking of the polymeric backbone to establish the final structure of the cell
membrane.
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Figure 1.3.1. Structure of peptidoglycan. The backbone of peptidoglycan constructed by
alternating β-1,4-linked glycan composed of N-acetylglucosamine (GlcNAc) and Nacetylmuramic acid (MurNAc), which in turn are cross-linked via their polypeptide chains.

The biosynthesis is carried out by 12 ubiquitous enzymes found in both Gram-positive as
well as Gram-negative bacteria, some of which still remain to be characterized in detail
[22] (Figure 1.3.2). In the initial cytosolic stage, the uridine-5’-phosphate (UDP)-sugars are
the biosynthetic starter molecules for all cell wall components and the process begins
with the transformation of the activated UDP-GlcNAc to UDP- MurNAc (catalyzed by
MurA and MurB), followed by attachment of a series of amino acids leading to the
polypeptide chain (L-Ala-γ-D-Glu-X-D-Ala-D-Ala where X is either L-Lys or Daminopimelate). The addition of the polypeptide chain is cumulatively carried out by a set
of ATP-dependent ligases Mur C-F. The resultant UDP-MurNAc-pentapeptide is then used
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to provide phospho-MurNAc-pentapeptide that is transferred to a membrane bound
undecaprenyl phosphate by the enzyme translocase I (phosphor-MurNAc-pentapeptide
translocase) or MraY. Addition of another GlcNAc sugar onto the 4’-OH of MurNAc
(catalyzed by the glycosyltransferase MurG) creates lipid intermediate II, which in turn, is
flipped outwards from the cytosolic side of the cell membrane presumably by a ‘flippase’
protein [23]. In some Gram-positive bacteria, additional amino acids are latched onto lipid
intermediate II from amino-acyl-tRNA donors (for examples, five Gly residues are added
on by FemABX in Staphylococcus aureus (26)). On the cell surface, lipid intermediate II is
polymerized via transglycosylation to afford a glycan polysaccharide which is then crosslinked via transpeptidation by the penicillin binding proteins (PBPs)

[24].

Transglycosylation relieves undecaprenyl pyrophosphate which can then be recycled via
enzymatic dephosphorylation [23].
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Figure 1.3.2. Peptidoglycan assembly. The reactions catalyzed by each enzyme is shown
in blue, and the natural products inhibiting specific steps in the pathway are highlighted
in red. Ramplanin can also bind to the product of MurG (Lipid II), while Vancomycin
inhibits the activity of transglycosylases by binding to the substrate.

Since most of the enzymes that partake in the biosynthesis of peptidoglycan lack
mammalian homologs, targeting cell wall biosynthesis has been proven successful as
traditional means for inhibiting bacterial survival and growth. Of the cytosolic stages, only
two of the enzymes are targeted by natural products fosfomycin and D-cycloserine [21],
whereas MurG is inhibited by cyclic peptides ramoplanin and enduracin [25]. Some
antibiotics like bacitracin target the lipid carrier itself, by binding irreversible to
undecaprenyl phyrophosphate [26]. The vancomycin group of glycopeptide antibiotics
inhibit the transglycosylation of lipid intermediate II, by binding to the substrate itself
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thereby preventing its interaction with the transglycosylase [27], and the β-lactams
irreversibly inhibit the final transpeptidation steps [24]. Natural product inhibitors have
been found for six of the biosynthetic steps, of which five have been tested clinically.
Although several have been successful as antibacterial antibiotics, many of them are
plagued with issues of resistance within years of clinical introduction. The inhibition of
the enzyme translocase I as a means of antibiotic activity, however, has not been fully
realized for clinical purposes yet, and therefore represents a unique frontier for discovery
of novel antibiotics.

1.4.

MraY – Structure and Function

MraY (phosphor-MurNAc-pentapeptide translocase) is an integral membrane enzyme
responsible for the second stage of peptidoglycan biosynthesis, in that, it catalyzes the
transfer of phosphor-MurNAc- pentapeptide from UDP-MurNAc-pentapeptide to the lipid
carrier

undecaprenyl-pyrophosphate,

generating

undecaprenyl-pyrophosphoryl-

MurNAc-pentapeptide or Lipid intermediate I [28] (Figure 1.4.1). This catalytic step is
Mg2+-dependent and essential for all bacterial viability, and therefore a promising
pharmacological platform for the development of new classes of antibiotics [29]. The
transferase activity of MraY was first discovered in 1965 by Neuhaus and coworkers [30],
although the gene for MraY remained unidentified until 1991 [29] when it was
overexpressed in E. coli and implicated for its putative transferase activity.
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Figure 1.4.1. Reaction catalyzed by MraY. MraY is a transmembrane protein responsible
for initiating the lipid-linked cycle of peptidoglycan biosynthesis.

MraY belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1phosphate transferase (PNPT) superfamily of enzymes, that also includes enzymes
responsible for the synthesis of cell envelope polymers like the O-antigen and teichoic
acid in bacteria, and the GPT (UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase) enzyme
family responsible for N-linked glycosylation in eukaryotes [31]. E. coli MraY has been
overexpressed, extracted into detergent micelles, and characterized kinetically using a
continuous fluorescence assay, but could not be purified to homogeneity (35). B. subtilis
MraY has also been purified in small quantities, although the specific activity is reduced
substantially upon purification (36). Earlier studies conducted with MraY isolated from
M. luteus [30] and S. aureus [32] in conjunction with the MraY from E. coli helped establish
it as a transmembrane protein indispensable for cell survival [33]. Studies conducted in E.
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coli involving mutational inactivation of the mraY gene led to growth inhibition and lethal
phenotype, typically observed from similar inactivation of genes involved in
peptidoglycan biosynthesis [34]. In addition to gram-negative E. coli, the mraY gene has
also been shown to be essential for survival in gram-positive bacteria Streptococcus
pneumonia, and bioinformatics studies have been conducted to suggest that only a single
copy of the essential mraY gene is encoded per genome based on all currently available
sequenced microbial genome [23]. Isotope enrichment experiments conducted with S.
aureus translocase I suggest a two-step reaction involving a proposed SN2 type
nucleophilic substitution mechanism via the formation of an intermediate [30]. The
structural basis of enzyme function was elusive for a long time in the absence of structural
information, until recently Lee and coworkers published the crystal structure of MraY
from Aquifex aeolicus at 3.3 Å resolution [35] (Figure 1.4.2).

11

Figure 1.4.2. X-ray crystal structure of MraY. The recently resolved structure of MraY
shows that it exists as a dimer with ten transmembrane helices with a visible tunnel at
the center of the dimer. Schematic for lateral view (bottom)
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MraY from Aquifex aeolicus (MraYAA) has been shown to crystallize as a dimer, generating
an oval-shaped tunnel at the center of the dimer [35]. The tunnel is predominantly
surrounded by hydrophobic amino acid residues and is large enough to presumably
accommodate lipids. Each subunit is comprised of 10 transmembrane helices, an
interfacial helix, a periplasmic β hairpin, a periplasmic helix and five cytoplasmic loops.
Mapping of conserved sequences onto the crystal structure revealed the highest
conservation localization around a cleft formed by the cytosolic and inner-leaflet
membrane regions of four of the transmembrane helices. Recent mutational studies
conducted in B. subtilis MraY established 14 invariant charged amino acid residues,
essential for enzyme activity [36] and most of these residues can be found in this ‘cleft’
region suggesting that this region serves as the active site. Three aspartate residues
(Asp117, Asp118 and Asp265) each found on a cytoplasmic loop, are strictly conserved
throughout the entire PNPT family and two invariant histidine residues (His 324 and His325)
in the MraY family have been shown to be catalytically important by mutational
inactivation, wherein, mutation of any of the three aspartate residues and one of the
histidine residues (His324) resulted in complete loss of activity. Based on these results, it
is proposed that Asp117 and Asp118 in MraYAA may be involved in Mg2+ coordination, and
Asp265 may be a possible active site nucleophile used in the formation of a covalent
enzyme-phospho-MurNAc-pentapeptide intermediate (Figure 1.4.3).
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Figure 1.4.3. Proposed catalytic site of MraY: Asp 116 (red), Asp 117 (blue) and Asp 265
(pink) are shown here along with bound Mg2+ ion (orange).

1.5.

Inhibitors of MraY

MraY has long been known as a promising target for the development of new antibiotics
because it is the target of several different classes of natural product inhibitors with
antibacterial activity as well as bacteriolytic lysis protein E from bacteriophage φX174 [36,
37]. Protein E (a 91-amino acid polypeptide) is another integral membrane protein
encoded by DNA phage φ-174 that leads to bacteriolysis via an unclear mechanism.
Mutational inactivation of Phe288, found near the extracellular face of the membrane was
shown to abolish protein activity [36]. An 18-residue polypeptide with the wild-type
sequences from Protein E was shown to possess the minimal requisites for lysis of host
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cells [38], whereas in another study, a 37-amino acid polypeptide containing the
transmembrane domain of protein E was shown to specifically bind and inhibit MraY [39].
Another category of MraY inhibitors is the lipopeptides amphomycin, friulimcin and
glycinocins [29]. These cyclic molecules are known to complex with undecaprenyl
phosphates in the presence of Ca2+, in a mechanism reminiscent of the glycopeptides like
vancomycin. Amphomycin is, therefore, a very potent inhibitor of Gram-positive bacteria
like streptococci and enterococci [40].

Peptidyl
Nucleosides
Lipodisaccharyl
Nucleosides
Nucleoside
Antibiotics

A90289/
Lipopeptidyl
Nucleosides

MraY Inhibitors

Protein E

Caprazamycin B
Muraymycin
Muraminomicn

Glycosyl-peptidyl
Nucleosides
Lipopeptides

Figure 1.5.1. Types of MraY Inhibitors.
To date, the largest reported group of MraY inhibitors is the nucleoside antibiotics, and
their activities are typically associated with the presence of key nucleoside components
in these molecules (Figure 1.5.1). They can be classified into four structural groups: 1) the
peptidyl nucleosides represented by pacidamycin from Streptomyces coeruleorubidus
[41] and mureidomycin from Streptomyces flavidovirens [42], 2) the lipodisaccharyl
nucleosides represented by tunicamycins from Streptomyces lysosuperificus [43], 3) the
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lipopeptidyl nucleosides represented by A-90289 from Streptomyces sp. SANK 60405 [44]
and caprazamycin from Streptomyces sp. MK730 -62F2 [45] and 4) the glycosyl-peptidyl
nucleosides represented by the capuramycins A-500359s from Streptomyces griseus
SANK 60196 [46], A-503083s from Streptomyces sp. SANK 62799 [47] and A-102395 from
Amycolatopsis sp. SANK 60206 [48]. Despite several notable structural variations between
the four groups, all of them share a key feature shown to be critical for their biological
activities: the presence of a nucleoside component that consists of high-carbon
furanoside, wherein the typical ribosyl component is replaced by a hexofuranoside( C6),
a heptafuranoside (C7), or in the case of tunicamycins, an undecafuranoside (C11) (Figure
1.5.2) [49].
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Figure 1.5.2. Representative nucleoside antibiotics. The key structural features are
highlighted in these compounds. The uracil component found in all of them is highlighted
in blue, and has been shown to be critical for activity in all of these inhibitors.

The variations in the structural components of each of these groups are presumably
responsible for the slight differences in their specific mechanism of inhibitions. The
peptidyl nucleosides share a typical 3’-deoxyuridine nucleoside attached via a 4’,5’enamide linkage to an N-methyl 2,3-diaminobutyric acid (DABA) residue, to which are
attached the amino acid residues typically found in this group. Mureidomycin, a
representative of this nucleoside type has been shown to be a competitive inhibitor
against UDP-MurNAc-pentapeptide [42, 50]. The tunicamycins contain an additional
GlcNAc moiety, a unique 11-carbon aminodialdose sugar or tunicamine [51] and an
amide-linked fatty acid attached to the tunicamine sugar. As such, they can act as
structural mimics of the diphospho-residue of UDP-MurNAc-pentapeptide leading to
17

competitive inhibition of MraY. Tunicamycins are additionally known for inhibiting the
GPT (UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase) enzyme family responsible for Nlinked glycosylation in eukaryotes, and are therefore poor pharmacological candidates
due to toxicity [52, 53]. On the other hand, the nucleoside inhibitors A-90289s,
caprazamycins, and the muraminomicins, muraymycincs all contain uridine, aminoribose,
diazepanone and fatty acyl moieties, with the major structural differences in the presence
or absence of their sugar appendages (Figure 1.5.3). Structure-activity relationship
studies using simplified synthetic analogues of these compounds have shown the uridyl
and aminoribosyl moieties as critical for optimal antibiotic activity [54, 55]. The
capuramycins A-500359s, A-500358s and A-102395 however lack the aminoribose, and
instead contains an unique caprolactam moiety which has been shown to be critical to its
activity [46, 56]. Despite these structural differences, all of these nucleoside antibiotics
have been shown to selectively inhibit MraY-catalyzed transferase activity. The
overarching aim in our lab has been the identification and characterization of the core
structural components responsible for inhibitory activity.
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Figure 1.5.3. Structurally related nucleoside antibiotics. Structural variations within the
liposidomycins are manifested by components in their side chains, while the core uracil
and aminoribose components are present in all of them.

1.6.

Current understanding of the biosynthetic pathways

As touched upon in the earlier sections, most of the nucleoside antibiotics contain highly
modified sugar nucleosides which are usually modified at the C-5’ of the parent ribose to
generate furanosides containing 6-11 carbons. Initial isotopic enrichment studies using
different high-carbon sugar nucleosides as models led to the realization that the glycosidic
bond with the nucleoside base is established prior to C-5’ modification, i.e. the nucleoside
is the starting precursor for direct C-C bond formation with other precursors (discussed
in the following section) as the other carbon source(s) [57-60]. The biosynthetic gene

19

clusters for several of these compounds, including the capuramycin-type antibiotics A500359s [61], A-503083s [62], liposidomycins [63], A-90289s [44], caprazamycins [64],
muraymycins [65], muraminomicins [66] and tunicamycins [67, 68] have been cloned and
sequenced. With the sole exception of tunicamycin, all the aforementioned gene clusters
have been shown to contain a shared orf that encodes a protein with sequence similarity
to proteins annotated as α-ketoglutarate: taurine dioxygenases (TauD) [69], which
catalyzes the conversion of taurine to aminoacetaldehyde and sulfite in E. coli, as means
of sulfite scavenging. Our current understanding of a proposed divergent pathway
beginning with a common precursor uridine-5’-monophosphate is illustrated in Figure
1.6.1 [70, 71].

Figure 1.6.1. Biosynthetic pathway towards nucleoside antibiotics. Functional
assignment of enzymes shown: (i) LipL: Fe(II): α-KG dioxygenase, (ii) LipK: L-threonine:
uridine-5’-aldehyde transaldolase, (iii) LipO: L-methionine: uridine-5’-aldehyde
aminotransferase, (iv) LipP: 5’-amino-5’-deoxyuridine phosphorylase, (v) LipM: UTP: 5amino-5-deoxy-α-D-ribose-1-phosphate uridyltransferase, (vi) LipN: 5-amino-5deoxyribosyltransferase.
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Cumulative characterization and functional assignment of the genes from A-90289 led to
the delineation of its biosynthetic pathway and elucidation of possible shared
intermediates leading to the capuramycins, caprazamycins and all other related
molecules. Following the generation of uridine-5’-aldehyde by LipL, the pathway
bifurcates – in one route, enzyme LipK (a L-threonine: uridine-5’-aldehyde transaldolase)
installs a 5’-C-glycyluridine unit via a pyridoxal-5’-phosphate (PLP) dependent reaction.
The resultant intermediate can serve as a template for further modifications (involving a
proposed decarboxylation event) leading to the capuramycin type antibiotics. The second
route involves a cascade of reactions resulting in the generation of the functionally crucial
aminoribose, which is then condensed with the intermediate produced by LipK by the
enzyme LipN, a 5-amino-5-deoxyribosyltransferase. Kaysser et al. [64] conducted a series
of gene deletion experiments resulting in the functional assignment of the enzyme Cpz21
as an acyltransferase responsible for installing the 3-methylglutaryl moiety in
caprazamycins (Figure 1.6.2)
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Figure 1.6.2. Side chain modifications in the caprazamycin pathway. The transfer of 3methylglutaryl-CoA is catalyzed by Cpz21 in caprazamycin biosynthesis.

Clues towards amide bond formation in the capuramycin pathway can be gleaned from
the enzyme CapW, identified as a putative Class C β-lactamase encoded within the
biosynthetic gene cluster for the capuramycins. CapW was found to catalyze a
transacylation resulting in the addition of an L-aminocaprolactam at the expense of the
methyl ester (Figure 1.6.3) [62]. The methyl ester was shown to be produced by CapS, an
S-adenosyl-L-methionine-dependent carboxylmethyltransferase that activates the
carboxylic acid component of the capuramycin precursor to the methyl ester, thereby
providing a kinetically competent substrate for the transacylase. The putative active site
Ser of CapW was mutated to Ala resulting in loss of enzyme activity, lending support to
the hypothesis that the reaction proceeds by a serine-dependent acylation/deacylation
mechanism typical of Class C β-lactamases.
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Figure 1.6.3. Amide-bond catalysis in capuramycin. Installation of the unique
caprolactam in capuramycins is achieved by concerted CapS and CapW reactions and
involved activation of the substrate by a methyl ester, followed by amide bond formation.

Another key observation is the predictive self-resistance mechanism in these antibiotics.
A gene encoding a putative aminoglycoside 3-phosphotransferase (referred to as ORF21)
within the gene cluster for the A-500359s was demonstrated to be highly expressed
during the production of the A-500359s, and was implicated in conferring self-resistance
when expressed in heterologous hosts E. coli and Streptomyces albus [61]. A similar gene
(capP) from the A-503083 gene cluster was shown to encode the enzyme CapP, an ATPdependent capuramycin phosphotransferase that regiospecifically transfers the γphosphate to the 3”-hydroxyl of the hexuronic acid moiety of A-503083 [72]. Kinetic
characterization of CapP with three major A-503083 congeners established that CapP
preferentially phosphorylates A-503083s containing an aminocaprolactam moiety
attached to the hexuronic acid. Consistent with these observations, the product obtained
from the CapP reaction lost its antibiotic activity against Mycobacterium smegmatis, and
this loss in bioactivity is primarily due to a 272-fold increase in the IC50 in the bacterial
translocase I-catalyzed reaction. Recent work in our group (Wenlong Cai) has established
an identical mechanism for resistance to A-102395.
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1.7.

Functional assignment of LipL

The orf from A-90289 was shown to encode the protein LipL which was functionally
assigned by our lab as a non-heme, Fe(II)-dependent α-ketoglutarate (α-KG): uridine-5’monophosphate (UMP) dioxygenase catalyzing the conversion of UMP to uridine-5’aldehyde during A-90289 biosynthesis [70]. The LipL reaction was modeled on the enzyme
TauD, the best studied member of a large and diverse superfamily of mononuclear, nonheme Fe(II)-dependent enzymes that are generally agreed to follow similar reaction
coordinates involving oxidative decarboxylation of α-ketoglutarate (hereby abbreviated
as α-KG) to presumably generate an enzyme-bound Fe(IV)-oxo intermediate during the
reaction. This strong oxidizing agent subsequently abstracts a hydrogen atom on the socalled prime substrate (UMP for LipL) to generate a carbon centered radical that leads to
an unstable hydroxylated intermediate [73, 74] (Figure 1.7.1).
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Figure 1.7.1. The reaction catalyzed by LipL. LipL catalyzes the first reaction in A-90289
biosynthetic pathway, and has been successfully characterized and modeled on the
reaction catalyzed by E. coli TauD (below).

The Fe(II)/ α-KG dependent enzymes are a mechanistically and functionally diverse
superfamily of enzymes responsible for a variety of reactions involved in protein sidechain modifications, repair of alkylated DNA/RNA, biosynthesis of antibiotics, lipid
metabolism and biodegradation of a number of compounds [75]. The conserved
structural element is a β-strand “jellyroll” fold typically containing three metal-binding
ligands found in a His1-X-Asp/Glu-Xn-His2 motif [76, 77]. The only exception can be found
in halogenases in this group, where the carboxylate ligand is absent [78] (Figure 1.7.2).
The co-substrate α-KG, chelated with the Fe(II) center via its C-2 keto group and C-1
carboxylate, is oxidatively decarboxylated to succinate, leading to the formation of the
Fe(IV)-oxo center responsible for hydroxylation of the prime substrate via a putative
“oxygen rebound” mechanism (or in other instances results in desaturation, cyclization,
ring closure/expansion etc.) [73, 74, 79, 80]. A few members show resemblances to this
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group in terms of protein structures or chemical mechanisms but somewhat unexpectedly
do not require α-ketoglutarate as a co-substrate [81].

Figure 1.7.2. ‘β- barrel jellyroll fold’ in DAOCS (Deacetoxycephalosporin C-synthase). The
eight parallel β-strands (indicated as β1-8) are conserved in all members of the enzyme
superfamily, despite the broad spectrum of substrates recognized by the enzymes of this
superfamily.

The putative reaction coordinates for representative enzymes from this group are
elaborated in the following chapters, with special emphasis on those closest in analogy to
the reactions catalyzed by LipL and Cpr19, the latter being the functional homolog Cpr19
from the A-102395 biosynthetic pathway. The ability to delve into intricate details of this
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intriguing toolbox of enzymatic machinery represents a fantastic platform to gain
improved understanding of their mode of action, to engineer these biocatalysts towards
generating novel scaffolds and facilitating future redesign. The focus of this thesis is an
in-depth characterization of LipL and its functional homolog Cpr19, with the major goal
to identify the putative reaction intermediates involved in its unique chemical
coordinates, along with additional efforts to elucidate the structural basis for the
reactivity by studying site-specific mutant variants of Cpr19.
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Chapter two: Elucidating the mechanism of LipL and Cpr19
2.1.

Background: Fe(II)/ α-ketoglutarate-dependent enzymes

We briefly review the amazing diversity of reactions catalyzed by members of this enzyme
superfamily and use specific examples to illustrate the same. Most representatives couple
the oxidative decomposition of α-KG to succinate and CO2 to the activation of their prime
substrates via the generation of a reactive oxygen species at the non-heme iron center.
The reactive oxygen species can then display alternative reactivity in related enzymes that
may result in hydroxylations, stereoinversions, desaturations, ring closure or ring
expansions (Figure 2.1.1).

Figure 2.1.1. Variable outcomes of reactions catalyzed by Fe(II): α-KG dependent
enzymes. Divergence of the proposed pathway resulting in (a) radical-group transfer, (b)
stereoinversion, or (c) desaturation outcomes

The first identified hydroxylase from this group was the enzyme prolyl-4-hydroxylase [82]
shown to be involved in the generation of trans-4-hydroxyprolyl products. In mammals,
this reaction is essential for the formation of collagens, elastins and several other proteins
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[83]. Several other enzymes from this group have since been shown to be required for
protein side chain modifications including lysyl hydroxylase [84], prolyl-3-hydroxylase,
aspartyl β-hydroxylase [85], etc (Figure 2.1.2).

Figure 2.1.2. Representative hydroxylation reactions. Reactions catalyzed by Prolyl-4hydroxylase (top) versus Prolyl-3-hydroxylases.

Some of these enzymes have been implicated in the repair of DNA/RNA – for example, E.
coli possesses the enzyme alkB that has been implicated in the direct repair of methylated
DNA and RNA lesions [86]. Expression of E. coli alkB in human cells was shown to confer
resistance to high concentrations of SN2 alkylating agents and in 2002, Trewick et al
demonstrated the direct repair of methylated DNA by AlkB in an Fe(II)-dependent process
that consumes oxygen plus α-KG and produces succinate and formaldehyde [87]. The
single isozyme of clavaminate synthase (CAS) exemplifies the versatility of Fe(II)/α-KG
dioxygenases by catalyzing three separate oxidative steps in the synthesis of clavulanic
acid. First identified in 1999 by Lloyd et al [88], the enzyme has been shown to hydroxylate
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the β-lactam precursor in the first step, followed by sequential cyclization and
desaturation in three different steps to yield the precursor for the final product (Figure
2.1.3).

Figure 2.1.3. Role of CAS. CAS is responsible for carrying out three distinct oxidative
reactions in this pathway. Abbreviations: CEAS: carboxyethylarginine synthase, BLS: βlactam-synthetase, PAH: proclaviminic acid aminidino synthase, CAS: Clavaminate
synthase, CAD: Clavaldehyde dehydrogenase

Another interesting member of this family is the enzyme CarC (carbapenem synthase)
involved in a desaturation reaction similar to CAS, but also exhibiting an additional
epimerization at the tertiary carbon atom that joins the two rings in the bicyclic product.
A recent article published in Science in 2014 [89] illustrates the unique mechanism of CarC
by which it carries out C5 stereoinversion in the biosynthesis of carbapenem antibiotics.
Following the attachment of a carboxymethylene unit to the C5 of L-proline of the 2pyrrolidine precursor unit, the Fe(IV)-oxo intermediate abstracts a hydrogen atom from
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C5, and the key residue tyrosine165 in CarC then proceeds to donate the hydrogen atom
to the opposite face of the resultant radical, an event that is sufficient to direct the
nonredox stereoinversion outcome that distinguishes CarC from other Fe(II)/α-KG
dioxygenases that typically proceed through a putative “oxygen-rebound” mechanism
(Figure 2.1.4).

Figure 2.1.4. Mechanism of CarC. CarC catalyzes both epimerization and desaturation
reactions in generating the (5R)-carbapenam scaffold. We elaborate more on this
mechanism in chapter three, alluding to its recently resolved crystal structure.

Few members of this group are additionally involved in the biosynthesis of plant products.
For example, the enzyme flavanone 3β-hydroxylase catalyzes a key step in flavonoid
biosynthesis [90] in which flavanones (for example naringenin illustrated in Figure 2.1.5)
are converted to the corresponding trans-dihydroflavonols. We have additionally
illustrated the reaction catalyzed by flavone synthase I in the same figure, since it also
utilizes flavones as substrates, but carries out a desaturation reaction resulting in the
introduction of a double bond in the final product [91]. Fe(II)/α-KG hydroxylases also
participate in lipid metabolism – two of the enzymes taking part in carnitine synthesis
have been characterized from humans [92] and phytanoyl-CoA hydroxylase is required
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for degrading the plant lipid phytanic acid [93]. The enzyme TauD from E. coli is involved
in the decomposition of alkyl sulfonates [73] along with the enzyme AtsK, from
Pseudomonas sp. that catalyzes the decomposition of alkyl sulfates, as opposed to
sulfonates, in a reaction mechanism identical to TauD [94]. A related biotransformation
has been observed for phosphorus scavenging in Pseudomonas stutzeri WM88, in which,
the genes htxA encodes the Fe(II)/α-KG hydroxylase HtxA capable of hydroxylating
reduced forms of phosphorus including hypophosphite (H3PO2) and phosphite (H3PO3)
[95].

Figure 2.1.5. Enzymes involved in Flavonoid biosynthesis. Flavone synthase I (red)
catalyzes desaturation of the substrate to introduce a double bond (top), while the
enzyme flavonone 3β-hydroxylase exhibits tandem hydroxylation/oxidation with the
same substrate.

Though the reactive Fe(IV)-oxo intermediate displays slight variations of the primary
activity in catalyzing desaturations, ring expansions, ring closures or other oxidative
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biotransformations within this group, all the enzymes described herein are agreed to
follow a more or less conserved mechanism which was formulated more than 20 years
ago by Hanauske-Abel and Günzler (solely on the basis of theoretical considerations) [96].
As more enzymes are added to this intriguing group and the spectrum of its functionalities
expand, we continue to broaden our understanding of the exact chemical coordinates
central to all of these reaction mechanisms.

2.2.

Reaction mechanism of Fe(II)/α-KG – dependent dioxygenases

Dioxygenases are vital enzymes with key functional roles in nature, utilizing molecular
oxygen and transferring both oxygen atoms to activated substrates [79, 97].
Monooxygenases, on the other hand, transfer a singular oxygen atom from molecular
oxygen while the other oxygen atom leaves in the form of water. The most well-known
monooxygenases, the P450s are some of the most versatile enzymes in the body involved
in such diverse functions such as detoxification of organic substrates in the liver to the
biosynthesis of hormones [98]. P450s are also a group of enzymes that utilize an oxo-iron
species for abstracting a hydrogen atom from their substrates, albeit with a heme iron
center involving a catalytic cycle that proceeds via two reduction and two protonation
steps. Although elusive, the oxo-iron species has been implicated by indirect evidence
from product distributions and kinetic isotope effects, and in case of peroxidases has been
fully characterized by crystallography, EPR and vibrational spectroscopy [98, 99]. A similar
oxo-iron species is central to the non-heme, Fe(II)/α-KG-dependent group of enzymes,
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however it remains elusive in terms of in-depth characterization [100]. So the interesting
question is, why are there two different classes of enzymes developed by nature for
essentially similar tasks: the hydroxylation of substrates via the activation of unreactive
carbon centers? This question can perhaps be addressed by the differences in the heme
and non-heme iron centers in these two groups, and the absence of a required cofactor
in case of the dioxygenases, which creates significant differences in the putative reaction
coordinates for the Fe(II)/α-KG-dependent enzymes (Figure 2.2.1).

Figure 2.2.1. Role of TauD in the body. The metabolism of cysteine in the body involves
both TauD and cysteine dioxygenase (CDO)

The most extensively studied member of non-heme Fe(II) dioxygenases is E. coli TauD,
implicated in the transfer of one of the oxygen atoms from molecular oxygen to α-KG,
and utilization of the second oxygen atom for putative hydroxylation of its prime
substrate taurine. Figure 2.2.2 shows the catalytic cycle of TauD based on cumulative
theoretical and experimental observations [101]. The cycle starts from resting state (A)
where the non-heme iron center is coordinated by two histidine (His 99, His205) residues, a
carboxylic acid group from Asp101 and three water molecules [73]. The first step is binding
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of α-KG generating a bidentate ligand (B) by the displacement of two of the coordinating
water molecules in the structure [102]. This intermediate complex has been isolated and
characterized as a Fe(II)/α-KG chromophore with absorption at 530 nm [103]. This step is
followed by sequential binding of the prime substrate taurine, which does not bind
directly to the center but displaces the remaining water molecule (which leads to the
complex C with absorption at 520 nm) allowing molecular oxygen to bind (D), initiating
the radical mediated sequential steps and simultaneously limiting the scope for
identification of the exact intermediates. It is however postulated that the dioxygen can
attack the α-KG leading to the formation of a five-membered ring structure (E), followed
by spontaneous decarboxylation of α-KG to succinate yielding the oxo-iron species in
complex F [104]. The reactive oxo-iron species can putatively abstract a hydrogen from
the prime substrate to afford a carbon centered radical on taurine (G), and rebound of
the hydroxyl group (“oxygen rebound”) to the reactive center forms the product complex
H. Release of products (succinate and hydroxylated taurine) and rebinding of water can
restore the catalytic center to its resting state (A) and initiate another catalytic cycle. This
mechanism has been corroborated with stopped-flow experiments which provided
evidence for at least two stable intermediates [102]: the first identified intermediate is
the oxo-iron complex that absorbs at 318 nm and develops after 20 – 25 ms, but decays
after 600 ms. Evidence for this intermediate can also be gleaned from oxygen isotope
studies using

16O/18O

labeled substrates [105], and from observations with

hydrogen/deuterium kinetic isotope effects using taurine and taurine-d2 which proved
that this complex is responsible for hydrogen abstraction [106]. The second identified
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intermediate corresponds to the complex H, formed after the oxo-iron species. Further
evidence from isotope labeled studies indicate the retention of each atom of oxygen, one
in succinate and the other in acetaldehyde [105]. However, this has never been detected
in the latter due to rapid solvent exchange.

Figure 2.2.2. Putative intermediates in the catalytic cycle of TauD. Intermediates A-H
have been identified by a combination of isotopic enrichment studies, stopped flow
experiments, spectroscopic and computational analyses. The only intermediates directly
identified are F and H.

For LipL and Cpr19, we begin by charting out a putative catalytic cycle modeled on TauD
(Figure 2.2.3), wherein the prime substrate UMP (1) can be putatively hydroxylated at C5 and thereafter dephosphorylated spontaneously to the final product uridine-5’36

aldehyde (2) and inorganic phosphate. The pathway is proposed to proceed via
intermediates a-h, starting with the ‘resting state’ where the Fe(II) center is coordinated
via the facial triad in the catalytic center, and three water molecules (a). Ordered
sequential binding of α-KG and UMP is proposed to cause conformational changes that
allow for binding of molecular oxygen to the catalytic center to form a Fe(III)-superoxo
species (d). The reaction can then proceed with attack of the distal oxygen on the α-keto
group of the bidentate coordinated α-KG, which in turn can lead to decarboxylation and
O-O bond cleavage to generate byproducts succinate, CO2 and and the high-spin Fe(IV)oxo intermediate (f). This intermediate is proposed to abstract the C-5’ hydrogen from
UMP, leading to the trigonal pyramidal complex ‘g’, as well as a carbon-centered radical
on UMP C-5’. ‘Oxygen rebound’ can lead to the hydroxylation at this position generating
the understandably short-lived 5’-OH-5’-phosphouridine, which can spontaneously
dephophorylate to the uridine-5’-aldehyde product following the TauD mechanism.
Though the catalytic cycle (described above) for TauD is widely accepted as a consensus
for this group of enzymes, in the context of the great spectrum of functional variability of
this group, another rational alternative can be envisioned for some of the later steps in
the catalytic cycle for LipL: a plausible alternative, in line with mechanisms demonstrated
for CarC and ANS [89], is a desaturation/enol-tautomerization mechanism, or a non-redox
conversion (CarC) that can take place following the first hydrogen abstraction step. An
alternative route for LipL via desaturase/enol tautomerization towards the final uridine5’-aldehyde product is additionally conceptualized and discussed in details in the

37

following section. We explore a number of strategies to provide a definitive distinction
between the two mechanisms and gain insights into the structural basis for the same.

Figure 2.2.3. Putative reaction coordinates for LipL (modeled on TauD and CarC); (A)
Proposed ‘hydroxylation’ mechanism proceeds through intermediates a-h, and cycles
back to a; (B) Alternative proposal for ‘desaturase’ mechanism bifurcates from
intermediate g, and proceeds through intermediates g-k, eventually cycling back to
resting state a; U:Uracil.

2.3.

Strategy for elucidating ‘Desaturase’ versus ‘Hydroxlation’ Hypothesis

For the desaturation hypothesis for LipL, in line with mechanisms demonstrated for CarC,
ANS, favone synthase etc., starting from proposed intermediate g, the reaction can be
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thought to proceed via sequential abstraction of both C-5’ and C-4’ hydrogens from UMP
followed by phosphate hydrolysis and enol tautomerization to yield the final aldehyde
product (uridine-5’-aldehyde). To be able to provide a clear distinction between the
hydroxylation and desaturation hypotheses for LipL, therefore, the key is to track the fate
of the C-4’ and C-5’ hydrogens. To monitor the fate of the C-4’ and C-5’ hydrogens, we
strategized the utilization of a selectively deuterated UMP as the prime substrate that
could be analyzed directly by mass spectrometric methods. As can be deduced from
Figure 2.2.3 (B), logic dictates that the retention of the deuterium label at the C-4’
position would negate the possibility of a second hydrogen abstraction event from UMP
in the original reaction, and thereby provide convincing evidence to eliminate a
desaturation mechanism. In line with this argument, we formulated the synthesis of a
selectively deuterated UMP analog ([2,3,4,5,5’-2H1]-uridine-5’-monophosphate) as the
primary substrate to be tested in reaction with LipL (and its homolog Cpr19 from the
strain A102395) and set out to track the fate of the C-4’-2H1 isotope label in the final
aldehyde product (Figure 2.3.1).

Figure 2.3.1. Strategy with deuterated UMP substrate (3). If the reaction were to follow
sequential abstraction from both C-4’ and C-5’ positions of 3, then the final aldehyde
product (4) would lose both 2H1 labels and have predicted MW 244.2.
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For the hydroxylation hypothesis following the TauD model, we theorized that a direct
evidence of hydroxylation can be observed from tracking the critical bridging
phosphoester oxygen in UMP (1). Since the phosphate group in UMP is a good leaving
group Figure 2.2.3 (A) it is difficult to establish the existence of the putative 5’-hydroxy5’-phosphouridine (C-5’-OH-UMP) intermediate due to its innate instability.

Figure 2.3.2. Strategy for utilization a modified substrate analog (11). We would attempt
entrapment of the elusive intermediate hydroxylated at the functionalized C-5’ position
(5)

To circumvent this challenge, we strategized the synthesis of a structural analog of UMP
(Figure 2.3.2) wherein the phosphoester oxygen bond O-P could be replaced by a C-P
bond to make the phosphonate derivative, effectively transforming the phosphate to a
poor leaving group. By doing so, and potentially entrapping the -OH at C-5’ position from
the reaction of LipL with the substrate analog (and preventing the intermediate from
converting back to the uridine-5’-aldehyde product by spontaneous dephosphorylation)
we could use it to mirror a similar hydroxylation step in the original reaction. To achieve
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this, we have adopted a synthetic strategy following on the method described by Xu et al.
[107] for the synthesis of phosphonates (Scheme 2.3.3).

Scheme 2.3.3. Synthesis of key substrate analog (11). Synthesis is planned via
retrosynthetic wittig condensation of protected uridine-5’-aldehyde (6a) and
corresponding ylide (4a).

2.4.

Materials and methods

2.4.1. Chemicals and Reagents
UMP, (1,2,3,4,5,6,6-2H1)glucose, 2- ketoglutaric acid (α-KG), β-nicotinamide adenine
dinucleotide 2’-phosphate reduced tetrasodium salt (β–NADPH), adenosine 5’triphosphate disodium salt (ATP), phosphor (enol) pyruvate trisodium salt (PEP), uracil,
uridine-5’monophosphate, and ascorbic acid were purchased from Sigma-Aldrich (St.
Louis, MO) or Promega (Madison, WI). Buffers, salts, organic solvents and media
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components were purchased from Sigma-Aldrich (St. Louis, MO) and Fisher Scientific
(Pittsburgh, PA). Synthetic oligonucleotides were purchased from Integrated DNA
Technologies 21 (Coralville, IA). Wizard® Plus SV Minipreps DNA Purification Systems,
Wizard® SV Gel and PCR Clean-Up System were purchased from Promega (Madison, WI,
USA). pET-30 Xa/LIC Vector Kit was purchased from Calbiochem (San Diego. CA, USA).
InstaGene Matrix was purchased from Bio-Rad (Hercules, CA). Ni-NTA agarose was
purchased from Qiagen (Valencia, CA). Amicon Ultra 10000 MWCO centrifugal filter was
purchased from Millipore (Billerica, MA). PD-10 desalting column was purchased from GE
Healthcare

(Pittsburgh,

PA).

DNA

sequencing

was

performed

using

the

BigDye™Terminator version 3.1 Cycle Sequencing kit from Applied Biosystems, Inc.
(Foster City, CA) and analyzed at the University of Kentucky Advanced Genetic
Technologies Center.

2.4.2. Instrumentation
UV/Vis spectroscopy was performed with a Bio-Tek μQuant microplate reader using
Microtest™

96-well

plates

(BD

Biosciences)

or

a

Shimadzu

UV/Vis-1800

Spectrophotometer. HPLC was performed with a Waters Alliance 2695 separation module
(Milford, MA) equipped with a Waters 2998 diode array detector and an analytical Apollo
C-18 column (250 mm x 4.6 mm, 5 μm) or a semi-preparative Apollo C-18 column (250
mm x 10 mm, 5 μm) purchased from Grace (Deerfield, IL). Electrospray ionization-MS was
performed using an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent
Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series Quaternary LC
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system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 5 μm, 80Å). High-resolution
MS was obtained from either University of Kentucky Mass Spectrometry Core Facility, or
from University of Minnesota, Department of Chemistry Mass Spectrometry Facility. NMR
data were collected using a Varian Unity Inova 400 or 500 MHz Spectrometer (Varian, Inc.,
Palo Alto, CA) at the University of Kentucky, and a Bruker Avance III 700 MHz
spectrometer equipped with a 5 mm QCI probe at the University of Wisconsin, Madison.
Malachite green binding assay was performed with a colorimetric-based Sensolyte MG
Phosphatase Assay Kit from AnaSpec, Inc. (Fremont, CA).

2.4.3. Bacterial strains and Enzymes
NovaBlue GigaSingles™ Competent Cells was purchased from Calbiochem (San Diego. CA,
USA). One Shot® BL21 (DE3) Chemically Competent E. coli was purchased from Invitrogen
(Camarillo, CA). TaKaRa LA Taq® DNA polymerase with GC Buffer was purchased from
Takara Bio Inc (Otsu, Shiga, Japan), T4 DNA ligase, NdeI, and Hind III were purchased from
New England Biolabs (Ipswich, MA). Expand long template PCR system was purchased
from Roche Applied Science (Indianapolis, IN). Commercial varieties of hexokinase,
pyruvate kinase, glucose-6-phosphate dehydrogenase, glutamate dehydrogenase,
phosphogluconate dehydrogenase, myokinase and inorganic pyrophosphatase were
purchased from Sigma-Aldrich (St. Louis, MO).
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2.4.4. Synthesis of 1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribohexofuranosyl]
uracil (11)
The synthetic strategy following on the method described by Xu et al. (122) for the
synthesis of phosphonates (Scheme 2.3.3) is used to generate the final substrate analog
(11). Table 1 summarizes the spectral characterization of compound 11, at the end of this
section.

(Diethoxyphosphinyl)methyl Triflate (2a): Trifluoromethanesulfonic

anhydride (35.5

mmol) was added dropwise to a stirred solution of commercially available diethyl
(hydroxymethyl)phosphonate (30.6 mmol) and 2,6-lutidine (37.6 mmol) in anhydrous
dicholoromethane (50 ml) at -50°C under N2 atmosphere. The reaction mixture was then
allowed to warm to 0°C over a period of 1.5- 2 hrs, and diluted thereupon by with ether
(300 ml). A precipitate formed upon addition of the diethyl ether, which was removed by
filtration and the filtrate was successively washed with water, 1 N HCl, and brine and then
dried over Mg2SO4. A yellowish oil was obtained upon concentration of the dried solution,
and this was used for the next step without further purification. 1H NMR (500MHz, CDCl3)
δ 1.37 (t, 6 H), 4.21-4.23 (m, 4 H), 4.61 (d, 2 H).
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[(Diethoxyphosphinyl)methyl] triphenylphosphonium Triflate (3a): 30 mmols of
[(diethoxyphosphinyl)methyl] triphenylphosphonium triflate (2) was added dropwise to
a stirred solution of triphenylphosphine (34.4 mmol) in anhydrous CH2Cl2 (50 ml) at 0 oC
under N2. The solution was left to reach room temperature and then stirred at this
temperature overnight. The CH2Cl2 was then evaporated under reduced pressure to about
one third of the volume, and the resultant oil was triturated with ether (200 ml). This led
to the formation of a white solid which was then collected by filtration. The final triflate
(2) was obtained after being washed with ether twice (50 ml x 2) as a white solid. Owing
to its relative instability, it was used directly in the next step. Analytical sample was
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prepared by rescrystallization from ethyl acetate/hexane. 1H NMR (500MHz, CDCl3) δ 1.16
(t, 6h), 4.0-4. 06 (m, 4H), 4.20 (dd, 2H), 7.66-7.86 (m, 15H)
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The

triphenylphosphonium triflate salt (3) (in anhydrous THF) was used directly for reaction
with a stirred suspension of NaH (1.25 mmol) in anhydrous THF (2 ml) at 0 oC under N2
and the reaction was allowed to proceed for about 0.5 h. The solvent was then removed
under reduced pressure and the resultant residue was extracted using CH 2Cl2. The
colorless oil obtained from concentration of the extracts was triturated with hexane to
yield another white solid. This solid too was unstable, and as such used directly for the
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next step. 1H NMR (500MHz, CDCl3) δ 1.08 (t, 6H), 1.28 (d, 1H), 3.88 (apparent quintet,
4H), 7.49-7.74 (m, 15H)
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2’,3’-O-isopropylidene-uridine (6a): 2,2-dimethoxypropane (270.68 mmol) was added to
a mixture of uridine (5) (20.48 mmol) and p-toluenesulfonic acid (1.75 mmol) in dry
acetone (166.5 mL, 0.123 M) and stirred at room temperature for 4 hrs. The color of the
solution turned yellow, and after removal of the solvent under reduced pressure the color
changed to deep purple. TLC analysis indicated completion of the reaction, and the dried
residue was used directly for purification via silica gel chromatography and eluted with
5% ethyl acetate in hexane. The final product was a white powder. 1H NMR (500MHz,
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CDCl3) δ 1.36 (s, 3H), 1.58 (s, 3H), 3.82 – 3.92 (m, 2H), 4.29 (m, 1H), 4.97 – 5.04 (m, 2H),
5.56 (d, 1H), 5.73 (m, 1H), 7.37 (d, 1H)
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2’,3’-O-isopropylidene-uridine-5’-aldehyde (7a): 2.476 mmols of IBX was added to a
solution of compound 6 (1.478 mmol) in dry acetonitrile(2.956ml, 0.5M) and stirred under
reflux conditions at 80°C for 2 hrs. Following completion of the reaction, the IBX was
removed by filtration through Celite followed by removal of the solvent under reduced
pressure. The resultant white solid was used for analysis. 1H NMR (500MHz, CDCl3) δ 1.36
(s, 3H), 1.52 (s, 3H), 4.53 (m, 1H), 5.12 – 5.17 (m, 2H), 5.62 (d, 1H), 5.78 (d, 1H), 7.45 (d,
1H), 9.4 (s, 1H), 10.25 (d, 1H)
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1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-D-ribo-hex-5-enofuranosyl]
uracil (8a): The triphenylphosphorane (4)(1.63 mmol) obtained earlier was added to a
stirred solution of 2’,3’-O-isopropylideneuridine (1.63 mmol) in anhydrous DMSO (200 ml)
at room temperature under N2. The reaction was allowed to proceed overnight, and TLC
analysis indicated completion of the reaction. The final ylide was extracted from the
DMSO medium using CH2Cl2 and purified via silica gel chromatography and elution with
5% methanol in CH2Cl2. 1H NMR (500MHz,CDCl3) δ 1.22 (t, 6H), 1.33 (s, 3H), 1.58 (s, 3H),
4.02 – 4.08 (m, 5H), 4.64 (dd, 1H), 4.93 (dd, 1H), 5.16 (ddd, 2H), 5.87 (d, 1H), 5.97 – 6.01
(dt, 1H), 6.77-6.82 (ddd, 1H), 7.72 (d, 1H), 11.43 (s, 1H)
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1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]
uracil (9a): 10% Pd/C (2 mg) was added to a solution of compound 8 (1 mmol) in methanol
(10 ml) and the reaction was allowed to proceed under H2 atmosphere overnight. The
mixture was then filtered through Celite for removal of the catalyst and was shown by
TLC to have been completely converted to the product. A yellowish oil was obtained upon
concentration of the solution, and this was used for the next step without further
purification. 1H NMR (500MHz, CDCl3) δ 1.25 (m, 9H), 1.47 (s, 3H), 1.72 – 1.95 (m, 4H),
3.94 (d, 1H), 4.03 (m, 4H), 4.56 (dd, 1H), 4.90 (dd, 1H), 5.56 (d, 1H), 5.66 (dd, 1H), 7.2 (d,
1H), 10.31 (s, 1H)
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1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribohexofuranosyl] uracil (11): In the final
step, TMSBr (1.626 mmol) was utilized for global deprotection of compound 9 (0.16
mmol) in CH2Cl2 (2 ml). After overnight stirring, the solvents were removed under reduced
pressure and the residue was dissolved in water and lyophilized to give pure compound
11. 1H NMR (500MHz, D2O) δ 1.82 – 1.94 (m, 4H), 3.95 – 3.98 (m, 2H), 4.27 (app t, 1H),
5.73 (d, 1H), 5.79 (d, 1H), 7.55 (d, 1H); 13C NMR (500MHz, D2O) δ 21.8, 22.88, 72.3, 73.15,
82.92, 89.6, 102.08, 141.65, 151.08, 165.70. HRMS (ESI+) calcd. for C10H15N2O8P [M + H]+
323.2098; found 323.0646.
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Figure 2.4.4.1. Spectroscopic characterization of S11. 1H, 13C, 2D 1H – 13C gHSQC
(500MHz, D2O) and HRMS for substrate analog 11.

Table 1. Assignment of each peak of the final substrate analog S11 to the corresponding
1H and 13C peaks obtained from the cumulative spectral data:

Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
21.73, CH2
22.82, CH
82.86, CH
72.24, CH
89.54, CH
73.09, CH
141.5, CH
102.2, CH
165.7, C
151.03, C
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δH
1.89, m
1.96, m
3.94
3.98, m
4.28, app t
5.79, d
7.55, d
5.74, d

2.4.5. Cloning of genes for heterologous expression
The genes were amplified by PCR using the Expand Long Template PCR system from Roche
with supplied buffer 2, 200mM dNTPs, 5% dimethyl sulfoxide, 10ng of DNA template, 5
units of DNA polymerase, and a 10mM concentration of each of the following primers
(Table 2). DNA templates for PCR cloning were either E. coli DH5α genomic DNA (EcRipA,
EcUpp), cosmid pN1 (lipL gene), pNCap02 (prepared using the genomic DNA
of Amycolatopsis sp. SANK 60206) (cpr19 gene) and Salmonella typhimirium plasmid
pBRS11R (from Dr. Vern L. Schramm, Albert Einstein University, New York)
(StPRPPsynthase). The thermocycler program included an initial hold at 94 °C for 10s, 56°C
for 15s, and 68°C for 50s. The DNA fragment of the expected sizes were purified by 1%
agarose gel and the purified PCR products were inserted into pET-30 Xa/LIC using ligationindependent cloning following the provided protocol to yield pET30- Ecprpp, pET30EcRipA, pET30-EcUpp, pET30-StPRPPsynthase, pET30-lipL and pET30-cpr19.

PCR-

amplified DNA was then sequenced to confirm its identity.
Table 2. List of primers used
Primers
StPRPPsynthase_for
StPRPPsynthase
_rev
EcRpiA_for
EcRpiAi_rev
EcUpp_for
EcUpp_rev
lipL_for
lipL_rev
cpr19_for
cpr19_rev

Oligonucleotide sequence
5’-GGTATTGAGGGTCGC ATGCCTGATATCAAGCTTTTTGCTGG-3’
5’-AGAGGAGAGTTAGAGCCTCAATGCTCGAACATGGCGGAAATC3’
5’-GGTATTGAGGGTCGCATGACGCAGGATGAATTGAAAAAAG-3’
5’-AGAGGAGAGTTAGAGCCTCATTTCACAATGGTTTTGACACC-3’
5’-GGTATTGAGGGTCGCATGAAGATCGTGGAAGTCAAAC-3’
5’-AGAGGAGAGTTAGAGCCTTATTTCGTACCAAAGATTTTGTC-3’
5’- GTGATTGAGGGTCGCATGTCCGTGCTGGGGCGG - 3’
5’- AGAGGAGAGTTAGAGCCTCATGAGGGCTTCTTGGTG – 3’
5’ - GGTATTGAGGGTCGCATGCAGCAGCTGCAAGCCG - 3’
5’- AGAGGAGAGTTAGAGCCTCAATTGGAGGCGCGGGG - 3’
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The plasmids were introduced into E. coli BL21 (DE3) cells by transformation and the
recombinant strains were grown in LB medium supplemented with 30 μg/ml kanamycin.
Recombinant culture were then grown at 18°C with 250 rpm, following inoculation with
500 ml of LB with 30 μg/ml kanamycin in a 2.5 L Erlenmeyer flask, until the cell density
reached an OD600 = 0.5. Expression was induced with 0.1 mM isopropyl 1-thio-β-Dgalactopyranoside (IPTG) and after overnight incubation at 18 °C, cells were harvested and
lysed using a French press with one pass at 15,000 psi and immediately centrifuged at
18,000 rpm. The obtained supernatant was utilized for purification of the desired proteins
using affinity chromatography with a nickel- nitriloacetic acid-agarose from followed by
desalting of the recombinant proteins into 50mM Tris-HCl (pH 8), 100mM NaCl, and 5%
glycerol using a PD-10 desalting column. The purified proteins were reconcentrated with
an Amicon Ultra 10000 MWCO centrifugal filter prior to addition of glycerol (final 40%)
for storage at -20°C. Protein solubility and purity were assessed by 12% acrylamide SDSPAGE; His6-tagged proteins were utilized without further modifications.
Table 3. List of plasmids used
Strain/Plasmid
E. coli Nova-blue
E. coli BL21 (DE3)
pET30
pET30- StPRPPsynthase
pET30- EcRpiA
pET30- EcUpp
pET30- lipL
pET30- cpr19

Characteristics and Relevance
Host for routine cloning
Host for protein expression
Expression vector
StPRPPsynthase gene cloned to pET30
EcRpiA gene cloned to pET30
EcUpp gene cloned to pET30
lipL gene cloned to pET30
cpr19 gene cloned to pET30
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References
Novagen
Novagen
Novagen
This study
This study
This study
This study
This study

2.4.6. Enzymatic synthesis of 2’,3’,4’,5’,5’’-2H1-uridine-5’-monophosphate(3)
Single reaction mixture (1 ml) consisted of 50mM Tris-HCl (pH 7.5), 10mM MgCl2, 5mM
uracil, 20 mM PEP, 1mM NADP+, 1mM ATP, 2.5 mM α-KG, 1mM NH4Cl, 1mM
(1,2,3,4,5,6,6’-2H1)glucose, 80 U of hexokinase, 160 U of pyruvate kinase, 100 U of
glucose-6-phosphate dehydrogenase, 160 U of glutamate dehydrogenase, 8 U of 6phosphogluconate dehydrogenase, 25 μg of phosphoriboisomerase (EcRpiA), 100 μg of 5phosphoribosyl-1-pyrophosphate synthetase (StPRPPsynthase), 25 μg of uracil
phosphopribosyl transferase (EcUpp), 80 U of myokinase and 5 U of inorganic
pyrophosphatase. The reaction was carried out at 30 °C overnight and terminated by
ultracentrifugation using a Microcon YM-3. Following removal of protein by
centrifugation, the reactions were analyzed by HPLC using a C-18 reverse-phased column
under ion-pairing conditions (monitored at 254 nm). A linear gradient of from 40 mM
acetic acetic acid-triethylamine pH 6.5 (A) to 20% methanol (B) (0-4 min, 0% B; 4-24 min,
50% B; 24-26 min 100% B; 26-32 min, 100% B; 32-35 min, 0% B) with flow rate of 1 ml/min
was used to analyze the reactions and elution was monitored at 260 nm. LC-MS was
performed using a linear gradient from 0.1% formic acid in water to 0.1% formic acid in
acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min, and elution was
monitored at 254 nm (Figure 2.4.6.1). Isolation of the deuterium labeled UMP product (3)
starting from universally deuterated glucose was carried out with HPLC using a C-18
reverse-phase column using the aforementioned ion-pairing conditions. The peak
corresponding to the product was collected and freeze-dried prior to mass-spectroscopic
analysis (discussed in section 2.5.2).
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Figure 2.4.6.1. Schematic for the synthesis of deuterated UMP analog (3). The pathway
is derived from an amalgamation of enzymatic steps from the glycolytic (red) and pentose
phosphate pathways (blue), as well as from nucleotide metabolism (green). Three of the
enzymes (His6-phosphoriboisomerase (His6-EcRpiA), His6-uracil phosphopribosyl
transferase (His6-EcUpp), and His6-5-phosphoribosyl-1-pyrophosphate synthetase (His6StPRPPsynthase) were synthesized in our lab; rest of the enzymes were available
commercially.

2.4.7. In-vitro reactions with LipL and Cpr19:
Reactions with LipL typically consisted of 50mM Tris-HCl (pH 7.5), 1mM UMP (or
2’,3’,4’,5’,5’’-2H1-UMP), 1.25 mM α-KG, 200 μM ascorbate, 100 μM FeCl2, and 100 nM LipL
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at 30°C. And reactions with Cpr19 typically consisted of 50mM Tris-HCl (pH 7.5), 1mM
UMP, 1.25 mM α-KG, 1 mM ascorbate, 500 μM FeCl2, and 100 nM Cpr19 at 30°C. Reactions
were terminated by ultracentrifugation using a Microcon YM-3. Following removal of
protein by centrifugation, the reactions were analyzed by HPLC using a C-18 reversephased column under ion-pairing conditions (monitored at 254 nm). A linear gradient of
from 40 mM acetic acetic acid-triethylamine pH 6.5 (A) to 20% methanol (B) (0-4 min, 0%
B; 4-24 min, 50% B; 24-26 min 100% B; 26-32 min, 100% B; 32-35 min, 0% B) with flow
rate of 1 ml/min was used to analyze the reactions and elution was monitored at 260 nm.
LC-MS was performed using a linear gradient from 0.1% formic acid in water to 0.1%
formic acid in acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min,
and elution was monitored at 254 nm.

2.4.8. Kinetic characterization of LipL and Cpr19:
The activities of LipL and Cpr19 were detected by monitoring the formation of inorganic
phosphate with the malachite green binding assay [108]. Detection of phosphate released
as an enzyme product is a well-established technique for assaying phosphatase activity.
For standardizing and quantifying the phosphate detected, the general procedure
involves removal of 60µL of the reaction mixture and adding 20 µL of the MG reagent
which is previously dispensed into individual wells in a 96-well format. The two were
mixed well and left to incubate at room temperature for 5 min. We used 20mM (20 µL)
EDTA (Ethylenediaminetetraacetic acid chelates Fe(II) from the enzyme) to terminate the
reactions with LipL and Cpr19. Absorbance was measured at 620 nm using a microplate
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reader. A standard curve was developed using phosphate standards of 0.8, 1.6, 3.2, 6.7,
12.5, 25, and 50 µM (provided in the kit). For single-substrate kinetic analyses involving
LipL and Cpr19, reactions consisted of 50mM Tris-HCl (pH 7.5), 1 mM ascorbate, 500 μM
FeCl2, 100 nM LipL, near saturating α-KG (1mM) and variable UMP (50 μM– 1 mM). The
reactions were initiated at 30°C by adding LipL (100 nM) or Cpr19 (100 nM) using the
pipettor for mixing. Reactions were terminated after 3 min (<10% product formation) by
addition of EDTA, using a sample without enzyme as a blank/control. Each data point
represents triplicate end point assays. Kinetic constants were obtained by nonlinear
regression analysis using GraphPad Prism.

For kinetic analysis of inhibition of LipL activity by synthesized substrate analog 11,
inhibition parameters were obtained by addition of variable concentrations of 11 (5 μM–
1 mM) to assays consisting of 50mM Tris-HCl (pH 7.5), 1 mM ascorbate, 500 μM FeCl2,
100 nM LipL, near saturating α-KG (1mM) and variable UMP (100 μM– 10 mM). For each
individual inhibition curve, we conducted the reactions by varying the concentration of
11 with a constant UMP concentration, and then repeating each study with a different
concentration of UMP. The reactions were performed at 30°C for 3 min and analyzed
under initial velocity conditions. Each data point represents a minimum of three replicate
end point assays. For analyzing the inhibition constants, we generated cumulative data
points from a total of five inhibition curves. We plotted a Lineweaver-Burke plot from the
cumulative data using GraphPad Prism to arrive at the inhibition constants.

60

2.4.9. NMR and mass spectrometric characterization of synthetic standards
We received two synthetic standards from our collaborator Dr. Suzanne Peyrottes
(University Montpellier, France) [109] that were used to test the identity of product
obtained from the reaction of Cpr19 with synthetic phosphonate substrate analog 11.
Compound UA1768 was received as a 91:9 mixture of the sodium salts of 1-[6’-Deoxy-6’phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil and 1-[6’-Deoxy-6’-phosphono-β-D-ribo(5’R)-hexofuranosyl]uracil. In compound UA1923, the ratio was reversed. HPLC analysis
(under ion pairing conditions) of the two reflect the elution profile and relative ratio of
the standards (Figure 2.4.9.1).

1-[6’-Deoxy-6’-phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil (Disodium salt) (UA1768):
Obtained as synthetic standard. 1H NMR (300MHz, D2O) δ 1.7 – 1.95 (m, 2H), 4.03 (t, 1H),
4.10 (m, 1H), 4.2 – 4.3 (m, 2H), 5.83 (d, 1H), 5.87 (d, 1H), 7.83 (d, 1H); 13C NMR (300MHz,
D2O) δ 31.6, 67.2, 68.7, 73.5, 87.5, 87.9, 102.6, 141.9, 151.9, 166.1. HRMS (ESI+) calcd. for
C10H16N2O9P [M – Na + 2H]+ 339.0593; found 339.0592.

1-[6’-Deoxy-6’-phosphono-β-D-ribo-(5’R)-hexofuranosyl]uracil (Disodium salt) (UA1923):
Obtained as synthetic standard. 1H NMR (300MHz, D2O) δ 1.70 – 1.90 (m, 2H), 4.01 (dd,
1H), 4.02 – 4.18 (m, 1H), 4.21 (dd, 1H), 4.3 (dd, 1H), 5.84 (d, 1H), 5.89 (d, 1H), 7.95 (d, 1H);
13C

NMR (300MHz, D2O) δ 32.0, 67.3, 70.3, 73.7, 87.0, 88.6, 102.4, 142.0, 151.8, 166.2.

HRMS (ESI+) calcd. for C10H16N2O9P [M – Na + 2H]+ 339.0593; found 339.0592.
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Figure 2.4.9.1. Synthetic standards. UA1768 consists of the major peak corresponding to
the S-hydroxy-phosphonate, and UA1923 contains R-hydroxy-phosphonate as the major
peak.

2.5.

Results

2.5.1. In vitro characterization of LipL and Cpr19:
In previous studies, the orf from A-90289 was shown to encode the protein LipL which
was functionally assigned by our lab as a non-heme, Fe(II)-dependent α-ketoglutarate (αKG): uridine-5’-monophosphate (UMP) dioxygenase catalyzing the conversion of UMP to
uridine-5’-aldehyde during A-90289 biosynthesis [70]. Cpr19 is a homolog of LipL from the
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strain A-102395 [110], and has been characterized similarly to carry out a net twoelectron oxidation of UMP to the final aldehyde product (Figure 2.5.1.1).

Figure 2.5.1.1. Reaction mechanism of LipL and Cpr19. Net two-electron oxidation of
UMP (1) to uridine-5’-aldehyde (2) catalyzed by homologs LipL (A-90289) and Cpr19 (A102395).

The lipL and cpr19 genes were cloned and expressed in E. coli to yield soluble protein with
the expected sizes (Figure 2.5.1.2). HPLC analysis of both reactions catalyzed by LipL and
Cpr19 revealed a peak corresponding to the product uridine-5’-aldehyde (2) and the trisadducts of the aldehyde eluting later (red and blue spectra) (Figure 2.5.1.3). Negative
control consists of the reaction mixture sans the enzymes, wherein substrate UMP (1)
elutes at t =12 min (black trace). LC-MS analyses of both reactions revealed (M-H)- ions at
m/z = 240.8, that confirms the identity of the aldehyde product from the reaction of both
enzymes (Figure 2.5.1.4).
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Figure 2.5.1.2. SDS-PAGE analysis of purified proteins (A) His6-LipL (expected 38.2 kD)
and (B) His6-Cpr19 (expected 31.7 kD)
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Figure 2.5.1.3. HPLC analyses of in-vitro reactions catalyzed by LipL and Cpr19. HPLC
trace for negative control (in the absence of enzymes) is depicted in black, and for the
reactions catalyzed by Cpr19 (red) and LipL (blue) complete conversion of the UMP (1)
peak (eluting at t =12 min) leads to the uridine-5’-aldehyde product (2) eluting at t = 5 min
(along with its corresponding mono- and bi- tris-adducts, as labeled). A260: absorbance at
260 nm.
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Figure 2.5.1.4. LC-MS analysis of the dioxygenase reactions. (A) Mass spectrum for the
ion peak eluting at t =3.9 min for the reaction catalyzed by LipL, (B) Mass spectrum for
the same peak, obtained from Cpr19 reaction.

2.5.2. In-vitro synthesis of 2’,3’,4’,5’,5’’-2H1-uridine-5’-monophosphate(3)
The genes for phosphoriboisomerase (EcRpiA), uracil phosphopribosyl transferase
(EcUpp) and 5-phosphoribosyl-1-pyrophosphate synthetase (StPRPPsynthase) were
cloned and expressed in E. coli to yield soluble protein with the expected sizes (Figure
2.5.1.1). HPLC analysis of the one-pot synthesis revealed a peak with retention time t =
12 min, as is expected for UMP (Figure 2.5.2.1). The peak was collected (as described in
section 2.4.6) and LC-MS was utilized for confirming the identity of the product, and to
establish the retention of four deuterium labels (Figure 2.5.2.3).
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Figure 2.5.2.1. SDS-PAGE analysis of purified proteins (i) His6- phosphoriboisomerase or
His6-EcRpiA (expected 22.8 kD), (ii) His6-Cpr19 (expected 31.7 kD), (iii) His6-uracil
phosphoporibosyl transferase or His6-EcUpp (expected 22.5 kD) and (iv) His6-5phosphoribosyl-1-pyrophosphate synthetase or His6- StPRPPsynthase (expected 34 kD).
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Figure 2.5.2.2. HPLC trace for the one-pot reaction. The pawthay is engineered from a
combination of reactions adopted from the glycolytic and pentose phosphate pathways,
and from nucleotide metabolism. The observed peak at t = 12 min corresponds to the
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desired deuterium labeled UMP product (3) from this reaction. A260: absorbance at 260
nm.
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Figure 2.5.2.3. LC-MS analysis of the peak collected from the one-pot reaction. (A) Mass
spectrum for the ion peak eluting at t = 4.08 min, corresponding to 2’,3’,4’,5’,5’’-2H1-UMP
(3) (calculated 329.3) (B) Mass spectrum for the peak eluting at t = 4.09 min, obtained
from injecting standard UMP (calculated 324.7). Comparison of the two LC-MS results
help in establishing the retention of five 2H1 labels in the synthesized product.

2.5.3. In-vitro utilization of 2’,3’,4’,5’,5’’-2H1-uridine-5’-monophosphate(3) by LipL and
Cpr19
The synthesized 2’,3’,4’,5’,5’’-2H1-uridine-5’-monophosphate(3) was tested in reaction in
vitro with both LipL and Cpr19. Initial activity tests with HPLC revealed that UMP (1) is
converted to uridine-5’-aldehyde (2), in line with previous observed spectra (Figure
2.5.1.2). Keeping with our earlier experiences with the inherent instability associated with
the aldehyde product, we did not try to collect the product peak from HPLC. Instead, we
directly injected the reaction mixture into the LC-MS and observed a peak with (M-H)- ion
at m/z=244.8 corresponding to 2’,3’,4’,5’,-2H1-uridine-5’-aldehyde (calculated 246.8). As
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negative control, we injected a reaction mixture obtained from the reaction of LipL
(and/or Cpr19) with standard UMP (1). This reaction mixture revealed a peak with (M-H)ion at m/z=322.7, corresponding to unlabeled uridine-5’-aldehyde (2) (Figure 2.5.3.1).
This result led to the conclusion that four 2H1 labels from (3) are retained in the
corresponding aldehyde product.
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Figure 2.5.3.1. LC-MS analysis of the peak collected from the reactions of LipL (A) and
Cpr19 (B) with 3. Mass spectrum for the ion peaks eluting at t = 4.08 min, corresponding
to 2’,3’,4’,5’,-2H1-uridine-5’-aldehyde (m/z=246.8) (C) Mass spectrum for the peak eluting
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at t = 4.09 min, obtained from injecting reaction mixture consisting of standard UMP with
LipL and (D) with Cpr19. The (M-H)- ion at m/z=240.8 corresponds to unlabeled uridine5’-aldehyde. These results confirm the retention of 2H1 labels at the C-4’ and C-5’ positions
in UMP.

2.5.4. In-vitro utilization of synthetic phosphonate substrate analog (11) by LipL and
Cpr19
Initial activity tests using HPLC revealed that LipL did not recognize synthesized analog 11
as a substrate. Variation of both substrate concentration and enzyme concentrations
proved futile (Figure 2.5.4.1). However, HPLC tests with Cpr19 and 11 were more
productive, with the observation of an (albeit small) product peak eluting directly ahead
of the substrate 11 peak (Figure 2.5.4.2).
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Figure 2.5.4.1. Reaction of LipL with S11. Comparative HPCL analyses of reactions carried
out with phosphonate substrate analog 11 with LipL, under variable concentrations of 11.
The observed peak corresponds to unutilized 11 in reaction. None of these studies yielded
a product peak. Inset: Absorbance maxima at 260 nm.
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Figure 2.5.4.2. Reaction of Cpr19 with S11. Comparative HPLC analyses of the reaction of
11 conducted with Cpr19. The major peak is 11, and the small peak at t =7 min is residual
uracil (decomposition product from reactions). (A) Negative control, which consists of the
reaction mixture without Cpr19. (B) Addition of Cpr19 to the reaction mixture yields a
product peak with absorbance at 260 nm (inset).
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2.5.5. Spectroscopic characterization of Cpr19 product
We used the synthetic standards received from our collaborators as a means for
confirming the identity of the product observed in the reaction of Cpr19 with substrate
analog 11. Comparative HPLC analyses of the negative control (reaction mixture in the
absence of Cpr19), synthetic standards, reaction mixture with Cpr19, and reaction
mixture co-eluting with synthetic standard UA1768 confirmed the identity of the
observed product peak as 1-[6’-Deoxy-6’-phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil
(5) (Figure 2.5.5.1).
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Figure 2.5.5.1. Comparative HPLC traces for confirming the identity of the Cpr19
product. (A) UA1768 synthetic standard, (B) Negative control consisting of 11 in reaction
mixture, in the absence of enzyme, (C) Formation of product peak from 11, catalyzed by
Cpr19, (D) Co-elution of reaction mixture with UA1768 indicates enrichment of the peak.
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2.5.6. Production of the Cpr19 product for NMR and mass spectroscopic analyses:
Large scale isolation of the Cpr19 product starting from synthesized UMP analog (11) was
carried out with HPLC using a C-18 reverse-phase semipreparative column using
previously described iron-pairing conditions. The peak corresponding to the product 1[6’-Deoxy-6’-phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil (5) was collected and freezedried prior to HRMS, 1D and 2D NMR spectroscopic analysis (Table 4, Figures 2.5.6.12.5.6.5 ). 1H NMR (600MHz, D2O) δ 1.89 (m, 2H), 4.09 (app t,1H), 4.14 (m,1H), 4.29 – 4.30
(m, 2H), 5.86 (d, 1H), 5.93 (d, 1H), 7.90 (d, 1H); 13C NMR (600MHz, D2O) δ 27.5, 67.5, 68.7,
73.5, 87.5, 102.2, 141.5, 151.9, 165.7. HRMS (ESI+) calcd. for C10H15N2O9P [M-H]:337.0463; found 337.04652.

Table 4. Assignment of each peak of the Cpr19 product (5) to the corresponding 1H and
13C peaks obtained from the cumulative spectral data:

Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
27.5, CH2
67.5, CH
87.5, CH
68.7, CH
73.5, CH
87.5, CH
141.5, CH
102.2, CH
165.7, C
151.9, C

δH (J in Hz)
1.89, m
4.14, m
4.09, app t
4.30, m
4.29, m
5.93, d (5.7)
7.90, d (8.1)
5.86, d (8.1)
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COSY
2
1
4
3
6
5
8
7

HMBC

9, 10

Figure 2.5.6.1. HRMS of the collected Cpr19 product peak with S11. Expected [M-H]:337.0463; found 337.04652.

Figure 2.5.6.2. 1H NMR (600MHz, D2O) for Cpr19 product peak (5).
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Figure 2.5.6.3. 2D 1H - 1H gCOSY (600MHz, D2O) for Cpr19 product peak (5).

Figure 2.5.6.4. 2D 1H – 13C gHSQC (600MHz, D2O) for Cpr19 product peak (5).
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Figure 2.5.6.5. 2D 1H – 13C gHMBC (600MHz, D2O) for Cpr19 product peak (5).

2.5.7. Kinetic characterization of LipL and Cpr19, with respect to substrate UMP
For single-substrate kinetic analyses involving LipL and Cpr19, reactions were conducted
at 30°C at pH=7.5. Reactions were terminated after 3 min (<10% product formation) by
addition of EDTA, using a sample without enzyme as a blank/control. Each data point
represents triplicate end point assays. Kinetic constants were obtained by nonlinear
regression analysis using GraphPad Prism (Figure 2.5.7.1). The extracted kinetic constants
are listed in Table 5.

75

LipL
Velocity (M/min)

Velocity (M/min)

8
6
4

-1

-1

Cat. Efficiency= 3 μM min

2

Cpr19

1.0
0.8
0.6
0.4

-1

-1

Cat. Efficiency= 1.76 μM min

0.2
0.0

0
0

500

0

1000

5000

10000

[UMP] (M)

[UMP] (M)

Figure 2.5.7.1. Kinetic analyses of LipL and Cpr19. Single-substrate kinetic analysis with
variable UMP (1) at pH=7.5 for LipL and Cpr19 obtained from malachite-green assay.

For kinetic analysis of inhibition of LipL activity by synthesized substrate analog 11,
inhibition parameters were obtained by addition of variable concentrations of 11 (5 μM,
10 μM , 50 μM , 500 μM and 1 mM) to assays consisting of 50mM Tris-HCl (pH 7.5), 1 mM
ascorbate, 500 μM FeCl2, 100 nM LipL, near saturating α-KG (1mM) and variable UMP
(100 μM– 10 mM). For each individual inhibition curve, we conducted the reactions by
varying the concentration of 11 with a constant UMP concentration, and then repeating
each study with a different concentration of UMP. The reactions were performed at 30°C
for 3 min and analyzed under initial velocity conditions. Each data point represents a
minimum of three replicate end point assays. For analyzing the inhibition constants, we
generated cumulative data points from a total of five inhibition curves. We plotted a
Lineweaver-Burke plot (Figure 2.5.7.2) from the cumulative data using Graphpad Prism
to arrive at the inhibition constants.
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Figure 2.5.7.2. Lineweaver-Burke plot for competitive inhibition of LipL by synthesized
substrate analog 11. The plot is obtained by plotting inverse substrate (UMP)
-1

-1

concentration (1/S) (in μM ) on the X-axis versus the inverse of velocity (1/V) (in μM min)
on the Y-axis, and then calculating Ki from the intercept on the Y-axis. The extracted
inhibition constant is Ki= 800 nM. Legend on the top represents the different
concentrations of 11 (in μM) used to generate each reciprocal graph.

77

Table 5. Kinetic constants for LipL and Cpr19
Enzyme

Substrate

LipL

UMP

LipL

UMP + (11)
(competitive
inhibitor)
UMP

Cpr19

2.6.

Km
(μM)
24 ± 10

kcat (min1)
72 ± 20

kcat / Km (μM1min-1)
3

Ki
(nM)
--

--

--

--

800

42 ± 14

74 ± 10

1.76

--

Conclusion

In summary, we have established that the dixoygenases LipL (from A-90289 pathway) and
Cpr19 (A-102395) proceed via a ‘hydroxylation’ mechanism to generate an unstable
hydroxylated intermediate by functionalizing prime substrate UMP (1) at C-5’. We can
rationally predict that this intermediate can spontaneously dephosphorylate to yield free
phosphate and the uridine-5’-aldehye (2) product that is utilized variously further down
the biosynthetic pathways for nucleoside antibiotics (Figure 1.6.1). Mass spectrometric
characterization of the product obtained from the utilization of selectively deuterated
UMP (3) by both LipL and Cpr19 in reaction provides indubitable evidence for rejecting
the ‘desaturase’ hypothesis, as was predicted earlier as an alternative pathway. The
surrogate hydroxylated intermediate (5) characterized as the Cpr19 product by employing
synthesized surrogate substrate (11) in reaction

mirrors a hydroxylated UMP

intermediate in the original reaction. The end result is a pathway highlighted in Figure
2.6.1. Our observations from this pathway can be rationally extended to the reaction

78

catalyzed by TauD in predicting the existence of the hydroxylated taurine intermediate,
which has remained elusive to date (67).

Figure 2.6.1. Revised biosynthetic pathway for dioxygenases LipL and Cpr19 via a
‘hydroxylation’ mechanism. (A) Employment of deuterated substrate UMP (3) resulting
in deuterated aldehyde product, (B) Utilization of synthetic substrate analog (11) to ‘trap’
hydroxylated intermediate (5).

2.7.

Discussion

Enzymes from the Fe(II): α-KG-dependent superfamily catalyze a diverse array of
biotransformations ranging from hydroxylations, stereoinversions, desaturations to ring
closure and ring expansions [75]. Bioinformatic analyses of several recently discovered
gene clusters for minimally two related families of nucleoside antibiotics revealed a
shared open reading frame encoding a protein with sequence similarity to TauD, the best
characterized member of this superfamily. We have characterized representative
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enzymes from the A-90289 and A-503083 gene clusters to reveal yet another diverse
biotransformation catalyzed by members of this superfamily. With this, we have thus
established uridine-5’-aldehyde as the starting intermediate for the biosynthesis of both
C7 high carbon nucleosides, as well as for the C6 high carbon nucleosides (Figure 1.6.1).
It is also reasonable to predict that other high carbon nucleoside antibiotics such as the
uracil-containing tunicamycin [68] and A-9464 [111], the adenine containing griseolic acid
[112], and cytosine-containing ezomycin A1 [113] may employ a similar enzymatic
strategy to initiate the organization of their respective high carbon sugar moieties (Figure
2.7.1). We can therefore use the information from our gene clusters as a platform to
rationally predict starting metabolites and similar biosynthetic assembly in related high
carbon sugar nucleosides. Interestingly, phosphate release by LipL has been
prognosticated as a potential additional function for this dioxygenase family, analogous
to sulfate and sulfite scavenging by TauD and AtsK [74], and we have demonstrated that
this is indeed plausible by providing the enzyme precedence for this chemistry.
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Figure 2.7.1. Platform for pathway prediction. High carbon sugar nucleosides with
predicted biosynthetic pathways that may include an activity similar to LipL and Cpr19.

Most of the biochemical characteristics for LipL and Cpr19 have been reported for other
enzymes of this family of enzymes. For example, activity for both enzymes is stimulated
by ascorbate, certain divalent metals inhibit activity, oxidative decarboxylation of α-KG
can still occur in the absence of prime substrate UMP [70]. For LipL, activity was shown to
be absolutely dependent upon the presence of α-KG and molecular O2, and isotope
enrichment studies conducted with 18O2 and H2O18 established the incorporation of one
of the oxygen atoms into the byproduct succinate. Unfortunately, the rapid and reversible
formation of a germinal diol in water did not allow the analysis of putative oxygen
incorporation into uridine-5’-aldehyde. While LipL is specific for both prime substrate and
α-KG and does not recognize substrate analog S11, Cpr19 recognizes both the substrate
analog as well as some other α-keto acids as cosubstrate (Wenlong Cai, unpublished
data). Keeping with our observations, we characterized S11 as a competitive inhibitor
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based on a lineweaver burke plot derived for its inhibitory effect on LipL activity (Ki=800
nM).
Clearly, the unique feature of LipL and Cpr19 is the specific utilization of UMP and the
mechanism by which net dephosphorylation and oxidative decarboxylation of α-KG takes
place. In our studies, we have provided convincing proof that, instead of tandem
phosphatase and oxidoreductase mechanisms as was postulated in earlier studies, the
reaction occurs via the generation of a cryptic hydroxyl germinal to a good leaving group
(phosphate) reminiscent of TauD and AtsK. A clear distinction between the hydroxylation
versus desaturation mechanisms can be gleaned by tracking the fate of labeled 2H1 atoms
from utilization of deuterated UMP substrate, as well from the key bridging C-6’ in the
synthesized phosphonate analog (S11). To the best of our knowledge, this is the first
direct identification of the hydroxylated intermediate (5) as the transient state in this type
of reaction, while also demonstrating the specific abstraction of the pro-S hydrogen atom
from C-5’ of UMP. The total enzymatic synthesis of deuterated UMP (3) via a combinatory
route derived from glycolytic, pentose phosphate and nucleotide metabolic pathways is
another distinctive platform that we developed as a substitute to chemical synthesis of a
deuterated analog. The most obvious advantage of this methodology is the convenience
of a one-pot setup and the stereospecific utilization of substrates eliminating the need
for stepwise purification, while the yield of the final product was a clear disadvantage.
The retention of five of the six deuterium labels starting from the universally deuterated
glucose substrate is possibly a result of recycled cofactors from within the one-pot
reaction.
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Chapter three: Exploring the structural basis of Cpr19 mechanism
3.1.

Background: Structural basis for mechanism of Fe(II)/α-KG dependent enzymes

The stereoselective oxidation of an unactivated alkyl C-H bond is possibly one of the most
difficult common functional group transformations in chemistry. Nature has tuned metaldependent oxygenases or oxidases to carry out such reactions. The most well
characterized enzymes that do so are the cytochrome P450 monooxygenases, and they
have been studied in explicit details both mechanistically and structurally [98, 99]. Nonheme oxidizing enzymes that require an α-keto acid as a cosubstrate constitute the
largest and most diverse family of mononuclear enzymes catalyzing many pivotal
metabolic transformations, some of which were highlighted in previous chapters. Despite
the vast array of distinct transformations these enzymes carry out, crystal structures of a
number of different members from this group show the double-stranded β-helix (or
jellyroll) as a common architecture for this superfamily [76, 77] (Figure 3.1.1) suggesting
a close evolutionary relationship between the three branches of the family identified by
sequence comparisons (diiron-using enzymes like methane monooxygenases, and
monoiron-using enzymes also including Fe(III) dependent enzymes like lipooxygenases)
[114, 115].
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Figure 3.1.1. ‘Jelly-roll’ fold in Clavaminic Acid Synthase (CAS). Crystal structure of CAS
complexed with mononuclear Fe(II) center (shown here in orange), complexed with
substrate PCV (5-amino-3-hydroxy-2-(2-oxo-azetidin-1-yl)-pentanoic acid) (shown in red)
and cosubstrate α-KG (in rainbow colors).

The highly conserved His1-X-Asp/Glu-Xn-His2 motif (facial triad) constitutes the facial
metal-binding ligands that binds the high-spin Fe(II) center. One of the oxygen atoms from
the dioxygen molecule has been shown to be incorporated into succinate, generated by
oxidative decarboxylation of α-KG [105]. Sequence analyses of members in this group
reveals little overall similarity, leading to the proposal that convergent evolution to a
common mechanism and active site chemistry occurred within the wider family of Fe(II)/
α-KG dependent and related oxygenases. The presence of such a metal binding motif is
not limited to iron-dependent enzymes – it is also known to occur in Mn(II)-dependent
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extradiol oxygenases and Zn (II)-dependent hydrolase enzymes like thermolysin [116]. In
Zn(II)-binding groups, the presence of an HEXXH…E motif provides the metal binding
glutamate and histidine ligands, very similar to the Fe(II)/ α-KG facial triad. The enzyme
peptide formylase from E. coli, originally characterized as a Zn(II)-dependent hydroxylase
has in fact been shown to utilize Fe(II) coordinated by two histidines and a cysteine
residue [117]. Cysteine residues are uncommon as ligands in the active site, predictably
since it would lead to reaction with molecular oxygen generating reactive oxidizing
species. However, the oxidation of an iron-linked thiol is elegantly exploited in the enzyme
isopenicillin N synthase (IPNS) [79].

Several enzymes in this class have substrates with a built-in α-keto acid function and
therefore do not require α-KG as a cosubstrate. Naturally, these enzymes appear to have
slightly dissimilar topologies from enzymes utilizing α-KG. Examples include HPP
dioxygenases, 4-hydromandelate synthase, 1-amino-1-cyclopropanecarboxylic acid
synthase (ACCO), isopenicillin N synthase (IPNS), etc. [79]. IPNS catalyzes the fourelectron oxidation of the tripeptide δ- (L-α-aminoadipoyl)- L- cysteinyl-D-valine (ACV) to
produce the penicillin nucleus and two water molecules [118]. The structure of IPNS was
the first reported structure for a member of this group [119] and provided an impressive
picture for the mechanism of this enzyme (Figure 3.1.2).
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Figure 3.1.2. Reaction mechanism of IPNS. IPNS catalysis involves forging a unique thiol
bond between the tripeptide substrate and the Fe(II) center of the enzyme. Dioxygen
binding in intermediate 3 leads to the abstraction of a hydrogen bond from the cysteinyl
residue, which paves the way to sequential deprotonation and β-lactam formation (6) by
IPNS.

The crystal structure of IPNS complexed with ferrous iron at resting state revealed a metal
ion octahedrally coordinated by His 214, Asp 216, His 270, Gln 330 and two water
molecules. Addition of the tripeptide ACV did not distort the ‘jelly-roll’ core, however the
side chain of Gln 330 which is coordinated to Fe(II) in the resting state is replaced by the
ACV thiolate. Additionally, one of the water molecules ligating the metal ion is displaced,
changing the metal coordination geometry from octahedral to square pyramidal (2 in
Figure 3.1.2). The valine isopropyl group of ACV is held in van der Waals contact with the
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iron by interactions with Leu231, Val 272, Pro 283 and Leu 223. Interestingly, the valine
βC-H bond, which is cleaved during the formation of the thiazolidine ring, is directed away
from the iron center in the initial substrate complex, implying that rotation of the valine
Cα-Cβ bond must occur during catalysis. The carboxylate of the valine residue of ACV is
prevented from coordinating directly to the Fe(II) center via a hydrogen-bonding network
in the resting enzyme complex. The aminoadipoyl residue of ACV was shown to be in an
extended conformation with its carboxylate group participating in forming a salt bridge
with Arg 87. Binding of substrate to enzyme complex initiates the reaction cycle and
allows for the coordination of molecular oxygen to the Fe(II) center leading to
intermediate 3, which presumably leads to the abstraction of the pro-3-S hydrogen of the
ACV cysteinyl residue. Subsequent deprotonation of the amide N-H by the hydroxosuperoxide species presumably allows for simultaneous β-lactam ring closure with
concomitant generation of the elusive Fe(IV)=O intermediate (5). It is reasonable to
assume that the isopropyl group must undergo a rotation parallel to β-lactam formation
to relive its steric interactions with the sulfur ligand, which also facilitates the interaction
of the valine β-hydrogen with the ferryl iron center (Figure 3.1.3).
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Figure 3.1.3. Crystal structure of IPNS depicting the ‘jelly roll’ topology. The Fe(II) center
(shown here in orange) is facially coordinated by His 214 (red), Asp 216 (yellow) and His
270 (blue). The residue shown in pink is Gln 330 which forms the initial coordination bond
with the ferrous iron center in the absence of ACV.

Since the reaction mechanism of both LipL and Cpr19 were shown to be similar to the
reaction catalyzed by TauD, the X-ray crystal structure of TauD complexed to Fe(II) and
both substrates (taurine and α-KG) provides a convincing model to predict the amino acid
residues responsible for the hydroxylation mechanism catalyzed by the enzymes under
investigation [120] (Figure 3.1.3). In fact, resolution of the TauD crystal structure led to a
predictive model of the enzyme TfdA, responsible for the first step of biodegradation of
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the herbicide 2,4-dichlorophenoxyacetate (2,4-D) [120] which in turn helped in
identification of the predicted residues in TauD and TfdA that undergo a selfhydroxylation mechanism observed in these enzymes, in the absence of prime substrate.

Figure 3.1.3. Crystal structure of a monomer of E. coli TauD. The Fe(II) center (shown
here in orange) is facially coordinated by His 99 (pink), Asp 101 (green) and His 255 (blue).
Primary substrate taurine (yellow) and cosubstrate α-KG (red) are shown bound to Fe(II)
center as well.

In TauD, the pentacoordinate Fe(II) is bound to the enzyme via the conserved facial triad,
composed of His 99, Asp 101 and His 255. Cosubstrate α-KG is bound via its C-1
carboxylate and C-2 keto group to the non-heme Fe(II) center, and via its C-5 carboxylate
which forms a salt bridge with Arg 266 and a hydrogen-bond with Thr 126. The amine end
of taurine can be stabilized by three hydrogen bonds with the phenolic side chain of Tyr
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73, the hydroxyl of Ser 158 and the amide oxygen of Asn 95. The taurine sulfonate is
similarly involved in hydrogen bond formation with Arg 270, His 70 and the backbone NH of Val102. His 70 is responsible for interacting with taurine, as well as form a hydrogen
bond with the backbone N-H of Val72. This lead to the realization that His 70 is possibly
uncharged and is most likely to form a hydrogen bond with the sulfonate group of taurine
(Figure 3.1.4).

Figure 3.1.4. Catalytic pocket of TauD. Stereodiagram of TauD showing the protein
ligands around the Fe(II) center. Shown here are the residues that form the facial triad
(His 99, Asp 101, His 255) (red), alongside the other amino acid residues (Thr 126, Arg 266
in blue) involved in stabilizing α-KG (depicted in dots). The residues interacting with the
amine end of primary substrate taurine are Tyr 73, Asn 95 and Ser 158 (green) while those
involved in interacting with the sulfonate moiety are Arg 270, His 70 and the N-H
backbone of Val 102 (orange).
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It is interesting to note that while Arg270 is relatively conserved for several members of
this enzyme family, the other two hydrogen bonds forged with Val72 and His70 help to
select for a tetrahedral sulfate anion. This leads to a key observation that His 70 is
conserved for the dioxygenases which specifically utilize sulfate or sulfonate substrates
(like AtsK) but is absent in other enzymes from this superfamily that bind substrates
containing a carboxylate moiety (like CarC, TfdA or CAS), and is therefore responsible for
imparting substrate selectivity to TauD.

Parallel to ongoing efforts to crystallize both LipL and Cpr19 in our lab, in this chapter we
explore some site specific mutants of Cpr19 developed either based on TauD as a model
or to provide mechanistic details. We explore the effects of these mutants on the activity
of Cpr19 to gain insights on the putative active site residues. Along the same lines, we
investigate substrate promiscuity of Cpr19 (as well as LipL) to investigate flexibility of
substrate recognition by testing its activity with four substrate analogs (xanthosine-5’monophosphate, S2, S3 and S4) that retain the ribose-5’-monophosphate moiety but
differ structurally from the ‘base’ component of the UMP nucleotide (Figure 3.1.5).
Bioinformatic analyses of homologous dixoygenases, as well as the development of in
silico models with docked substrates helps in providing a predictive model for these
enzymes, assimilating the information obtained from site specific mutants.
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Figure 3.1.4. Structural substrate analogs of UMP. These analogs were generated by
enzymatic synthesis for testing substrate promiscuity of Cpr19 and LipL with alternative
substrates. They were generated previously in our lab from uptake of xanthine and uric
acid in reaction, and were characterized preliminarily as isomeric pairs differing in their
connections by mass spectrometric data.

3.2.

Materials and Methods

3.2.1. Chemicals and Instrumentation
Uridine-5’-monophosphate (UMP), 2- ketoglutaric acid (α-KG), xanthine, uric acid, PRPP,
Nucleoside bases, nucleosides, and nucleotides were purchased from Sigma or Promega.
Buffers, salts, and media components were purchased from Fisher Scientific. Synthetic
oligonucleotides were purchased from Integrated DNA Technologies. DNA sequencing
was performed using the BigDye™Terminator version 3.1 Cycle Sequencing kit from
Applied Biosystems, Inc. and analyzed at the University of Kentucky Advanced Genetic
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Technologies Center. UV/Vis spectroscopy was performed with a Bio-Tek μQuant
microplate reader using Microtest™ 96-well plates or a Shimadzu UV/Vis-1800
Spectrophotometer. HPLC was performed with a Waters Alliance 2695 separation module
(Milford, MA) equipped with a Waters 2998 diode array detector and an analytical Apollo
C-18 column (250 mm x 4.6 mm, 5 μm) or a semi-preparative Apollo C-18 column (250
mm x 10 mm, 5 μm) purchased from Grace. Electrospray ionization-MS was performed
using an Agilent 6120 Quadrupole MSD mass spectrometer equipped with an Agilent
1200 Series Quaternary LC system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 5
μm, 80Å). NMR data were collected using a Varian Unity Inova 500 MHz Spectrometer.
High Resolution Mass Spectrometric data were obtained from University of Kentucky
Mass Spectrometry Core Facility.

3.2.2. Site directed mutagenesis
Point mutations of Cpr19 were generated by PCR amplification using pET30-cpr19 as a
template and the Expand Long Template PCR system (Roche Applied Science
(Indianapolis, IN)). Reactions were conducted as described in the provided protocol with
supplied buffer 2, 5% dimethyl sulfoxide, each of the following primers (Table 6) and the
reverse compliment (the engineered Ala component is underlined below for the mutant
variants). The thermocycler program included an initial hold at 94°C for 10s, 56°C for 15s,
and 68°C for 50s. The template DNA was digested with DpnI for 1h at 68°C and
transformed into E. coli DH5α competent cells. Introduction of the desired point
mutations and the sequence of the entire gene including 200bp upstream and
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downstream were confirmed by DNA sequencing to yield the desired set of Cpr19
mutants as listed in the table below (Table 7). The nikR gene was amplified by PCR cloning
from genomic DNA isolated from Streptomyces tendae, following the protocol described
in Section 2.4.5.
Table 6. List of primers used for site-directed mutagenesis
Primers

Oligonucleotide Sequence

cpr19(S79A)_for

5’ – CGGAGAGACCAAGGACTACGCCGCGCCCTACAGCGAC – 3’

cpr19(T119A)_for

5’ – CATCGGCGAAATCAAGACCGCGATCCTGTACTGCGTCCG – 3’

cpr19(W104A)_for

5’ – CACGACGGCCGGTCAGATTGCGCACGTGGACGGTCTCCT – 3’

cpr19(H105A)_for

5’ – GACGGCCGGTCAGATTTGGGCCGTGGACGGTCTCCTCGATG -3’

cpr19(D107A)_for

5’ – GGTCAGATTTGGCACGTGGCCGGTCTCCTCGATGACATCG – 3’

cpr19(C123A)_for

5’ – CAAGACCACGATCCTGTACGCCGTCCGGGCCGCTCACC – 3’

cpr19(C198A)_for

5’ – ACACCGACAACGAGACGGCCACGTGGGACTACTCGGCCGAT– 3’

cpr19(R260A)_for

5’ – CAAGCCGGACGCCCGCGCCCACCTGGTCAGGGCGCTC – 3’

nikR_for

5’- AGAGGAGAGTTAGAGCCTCAGTCGTCCGTGCCGAAG - 3’

nikR_rev

5’- GGTATTGAGGGTCGCATGACGCAGGATGAATTGAAAAAAG – 3’

3.2.3. Cloning and heterologous expression of genes
Plasmids were introduced into E. coli BL21 (DE3) cells by transformation and the
recombinant strains were grown in LB medium supplemented with 30 μg/ml kanamycin.
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Recombinant culture were then grown at 18°C with 250 rpm, following inoculation with
500 ml of LB with 30 μg/ml kanamycin in a 2.5 L Erlenmeyer flask, until the cell density
reached an OD600 = 0.5. Expression was induced with 0.1 mM isopropyl 1-thio-β-Dgalactopyranoside (IPTG) and after overnight incubation at 18 °C, cells were harvested and
lysed using a French press with one pass at 15,000 psi and immediately centrifuged at
18,000 rpm. Obtained supernatant was utilized for purification of the desired proteins
using affinity chromatography with a nickel- nitriloacetic acid-agarose from followed by
desalting of the recombinant proteins into 50mM Tris-HCl (pH 8), 100mM NaCl, and 5%
glycerol using a PD-10 desalting column. Purified proteins were concentrated with an
Amicon Ultra 10000 MWCO centrifugal filter prior to addition of glycerol (final 40%) for
storage at -200°C. Protein solubility and purity were assessed by 12% acrylamide SDSPAGE; His6-tagged proteins were utilized without further modifications.
Table 7. List of plasmids used for site-directed mutagenesis
Strain/Plasmid

Characteristics and Relevance

References

E. coli Nova-blue
E. coli BL21 (DE3)
pET30
pET30- cpr19(S79A)
pET30- cpr19(T119A)
pET30- cpr19(W104A)
pET30- cpr19(H105A)
pET30- cpr19(D107A)
pET30- cpr19(C123A)
pET30- cpr19(C198A)
pET30- cpr19(R260A)
pET30- nikR

Host for routine cloning
Host for protein expression
Expression vector
cpr19(S79A) gene cloned to pET30
cpr19(T119A) gene cloned to pET30
cpr19(W104A) gene cloned to pET30
cpr19(H105A) gene cloned to pET30
cpr19(D107A) gene cloned to pET30
cpr19(C123A) gene cloned to pET30
cpr19(C198A) gene cloned to pET30
cpr19(R260A) gene cloned to pET30
nikR gene cloned to pET30

Novagen
Novagen
Novagen
This study
This study
This study
This study
This study
This study
This study
This study
This study
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3.2.4. In-vitro characterization of Cpr19 mutant variants
Reactions with each Cpr19 mutant typically consisted of 50mM Tris-HCl (pH 7.5), 1mM
UMP (or substrate analog S11), 1.25 mM α-KG, 1 mM ascorbate, 500 μM FeCl2, and 100
nM enzyme at 30°C. Reactions were terminated by ultracentrifugation using a Microcon
YM-3. Following removal of protein by centrifugation, the reactions were analyzed by
HPLC using a C-18 reverse-phased column under ion-pairing conditions (monitored at 254
nm). A linear gradient of from 40 mM acetic acetic acid-triethylamine pH 6.5 (A) to 20%
methanol (B) (0-4 min, 0% B; 4-24 min, 50% B; 24-26 min 100% B; 26-32 min, 100% B; 3235 min, 0% B) with flow rate of 1 ml/min was used to analyze the reactions and elution
was monitored at 260 nm.

3.2.5. Kinetic characterization of Cpr19 mutants
The activities of the generated Cpr19 mutants were detected by monitoring the formation
of inorganic phosphate with the malachite green binding assay as described in the
previous protocol [108]. As before, we used 20mM (20 µL) EDTA to terminate the
reactions of the Cpr19 mutants with substrate UMP. Absorbance was measured at 620
nm using a microplate reader. A standard curve was developed using phosphate
standards of 0.8, 1.6, 3.2, 6.7, 12.5, 25, and 50 µM (provided in the kit). For singlesubstrate kinetic analyses involving Cpr19 mutants, reactions consisted of 50mM Tris-HCl
(pH 7.5), 1 mM ascorbate, 500 μM FeCl2, 100 nM enzyme, near saturating α-KG (1mM)
and variable UMP (50 μM– 1 mM). The reactions were initiated at 30°C by adding each
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Cpr19 mutant (100 nM) using the pipettor for mixing. Reactions were terminated after 3
min (<10% product formation) by addition of EDTA, using a sample without enzyme as a
blank/control. Each data point represents triplicate end point assays. Kinetic constants
were obtained by nonlinear regression analysis using GraphPad Prism.

3.2.6. Enzymatic synthesis of structural substrate analogues of UMP
Reactions with NikR and EcUpp typically consisted of 50mM HEPES buffer (pH 7.5), 2mM
xanthine (or uric acid), 2.5mM PRPP, 20mM MgCl2 and NikR/EcUpp (100 nM) at 30°C.
Following removal of protein by centrifugation, the reactions were analyzed by HPLC
using a C-18 reverse-phased column (monitored at 254 nm). A series of linear gradients
was developed from 0.1 % TFA in 5 % acetonitrile (A) to 0.1 % TFA in 90% acetonitrile (B)
in the following manner (beginning time and ending time with linear increase to % B): 04 min, 100% B; 4-24 min, 50% B; 24-26 min, 100% B; 26-32 min, 100% B; and 32-35 min,
0% B. LC-MS was performed using a linear gradient from 0.1% formic acid in water to 0.1%
formic acid in acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min,
and elution was monitored at 254 nm.

3.2.7. In vitro utilization of substrate analogs by LipL and Cpr19
Reactions typically consisted of 50mM HEPES buffer (pH 7.5), 1mM each of the substrate
analogs (xanthosine 5’-monophosphate (XMP), S2, S3 or S4), 1.25 mM α-KG, 200 μM
ascorbate, 100 μM FeCl2, and 100 nM LipL or Cpr19 at 30°C. Reactions were terminated
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by ultracentrifugation using a Microcon YM-3. Following removal of protein by
centrifugation, the reactions were analyzed by HPLC using a C-18 reverse-phased column
under ion-pairing conditions (monitored at 254 nm). A linear gradient of from 40 mM
acetic acetic acid-triethylamine pH 6.5 (A) to 20% methanol (B) (0-4 min, 0% B; 4-24 min,
50% B; 24-26 min 100% B; 26-32 min, 100% B; 32-35 min, 0% B) with flow rate of 1 ml/min
was used to analyze the reactions and elution was monitored at 260 nm. Large scale
isolation of the respective reaction products starting from one of four substrate analogs
(XMP, S2, S3 or S4) were carried out with HPLC using a C-18 reverse-phase
semipreparative column. The linear gradient utilized was exactly identical to the gradient
used for analytical characterizations. However, the flow rate was kept constant at 3.5
mL/min, and elution was monitored at 254 nm. LC-MS was performed using a linear
gradient from 0.1% formic acid in water to 0.1% formic acid in acetonitrile over 20 min.
The flow rate was kept constant at 0.4 mL/min, and elution was monitored at 254 nm.

3.2.8. Development of in-silico models for Cpr19 and LipL structures
Cpr19 model: The SWISS-MODEL [121] predicted Cpr19 structure elements were aligned
with the crystallographically determined structure of E. coli TauD (PDB ID: 1GQW)
template. The Cpr19 sequence was modeled onto the TauD chain A ignoring Fe(II), α-KG
and primary substrates using PyMOL [122]. Cpr19 residues for which there were no
equivalent residue in TauD were masked. From the initial model, we encountered a gap
in the TauD structure (between residues Tyr162 and His171) and as a result the predicted
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structure for Cpr19 did not align well with this region. The predicted model suggested an
additional α-helix in Cpr19 for this region, and in the absence of a convincingly superior
model we decided to omit residues 160-182 from the template to gain a better model.
Fe(II) and α-KG were inserted into the Cpr19 model based on the alignment of its 2 His –
1 carboxylate facial triad with that of TauD, with direct substitution of the α-KG and Fe(II)
positions. The residues interacting with the carboxylate of α-KG (Thr 133 and Arg 260)
were in perfect alignment with the equivalent residues in TauD. Primary substrate UMP
(1) was manually positioned onto the modeled Cpr19 active site using AutoDock Vina
[123]. As an initial constraint, we rationalized that the phosphate moiety of UMP must
align with the analogous sulfate moiety of taurine in TauD, and superimposed UMP
accordingly. Since we showed in the preceding chapter that Cpr19 selectively oxidizes the
pro-S hydrogen of UMP, this hydrogen was positioned to face the active site Fe(II). We
proceeded to model the other four substrate analogs (XMP, S2, S3, S4) in the active site,
following the same protocol.
LipL model: For this model, the previously predicted Cpr19 homology model was used as
a template to generate the structural elements for LipL via SWISS MODEL, as before. The
LipL sequence was modeled onto the Cpr19 model with Fe(II) and co-substrate α-KG using
PyMOL, resulting in nearly perfect alignment of the active site residues as expected.
AutoDock Vina was used to manually dock UMP into the active site following on the same
rationale that was used for the Cpr19 model.
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3.3.

Results

3.3.1. Bioinformatic analyses of LipL and Cpr19 with homologous dioxygenases
Since iron binding by the mononuclear non-heme, α-KG binding dioxygenases from this
superfamily of enzymes is mediated by the facial binding triad, the conserved essential
motif is HX1D/EXnH, wherein Xn can vary between 40 to 153 amino acids. For aligning the
sequences of LipL and Cpr19 with the sequence of TauD we used the ClustalW Omega
online program. An example of a sequence alignment of TauD (accession number
AAB18091.1) with LipL (accession number BAJ05888) and Cpr19 is shown in Figure
3.3.1.1. We confirm the presence of the Fe(II) binding motif essential for enzyme catalysis
(shown in the black rectangular boxes, with the three residues highlighted in pink).
Residues that are similar are highlighted in grey, and the conserved residues are
highlighted in light blue. As is evident from this alignment, LipL and Cpr19 share very little
sequence identity with TauD (less than 20%) which is expected since most other members
from this superfamily usually have very little sequence similarities given the great
diversity in their substrates [120].
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Figure 3.3.1.1. Sequence analyses of TauD (blue), LipL (orange) and Cpr19 (red) using
ClustalW. Conserved regions are boxed and contain the residues critical for binding the
non-heme Fe(II) center. While TauD has 153 residues between the 2nd and 3rd ligands, LipL
and Cpr19 both have 140 residues between those two.

The enzyme alkylsulfutase AtsK from Pseudomonas putida [124] is a close homolog of
TauD that catalyzes the hydroxylation of an alkyl sulfate ester which similarly decomposes
to sulfate and an aliphatic aldehyde. We used this as a second template (accession
number YP_008111264) to conduct sequence analyses of LipL and Cpr19 using the
ClustalW program. We observed a similar set of aligned residues (highlighted as before)
101

with the Fe(II)- binding motif shown in the conserved boxed regions, confirming that the
sulfate releasing enzymes share very low sequence identity with LipL and Cpr19 (Figure
3.3.1.2).

Figure 3.3.1.2. Sequence analyses of AtsK (blue), LipL (orange) and Cpr19 (red) using
ClustalW. As before, the conserved regions are boxed and represent the residues critical
for binding Fe(II). AtsK has a 155 residue spacer between the 2nd and 3rd ligands.
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3.3.2. In vitro characterization of Cpr19 mutant variants:
The genes for the set of Cpr19 mutants (Table 7) were cloned and expressed in E. coli to
yield soluble proteins. HPLC analysis of the reactions catalyzed by each of the mutant
variants revealed either a peak consistent with the product uridine-5’-aldehyde (2) (and
the tris-adducts of the aldehyde eluting later) if the site-specific mutant did not exhibit
altered activity, or a peak corresponding to unutilized UMP (1) if the corresponding point
mutation was responsible for abolishing activity in the mutant (Figure 3.3.2.1). The subset
of mutants that exhibited abolished or partial activity are depicted separately in Figure
3.3.2.2.
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Figure 3.3.2.1. Color coded HPLC traces for reactions catalyzed by generated set of
Cpr19 site specific mutants. Observed peaks for uridine-5’-aldehyde (2) and related trisadducts indicate retention of activity for mutants S79A, W104A, T119A, C123A, C198A
and partial conversion for H105A. Abolishment of activity in D107A and R260A mutants
are inferred from the unutilized substrate UMP (1) peak eluting at t = 12 min. A260:
absorbance at 260 nm.
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Figure 3.3.2.2. Subset of mutant enzymes that exhibited altered activity. H105A was
shown to partially convert UMP (1) to uridine-5’-aldehyde (2), while the activities for both
D107A and R260A were completely abolished. A260: absorbance at 260 nm.

3.3.3. In vitro utilization of substrate analog S11 by Cpr19 mutant variants
As an additional characterization of the Cpr19 mutants, we wanted to test if the mutants
could recognize synthesized analog S11 as a substrate (with regards to substrate analog
recognition in wild-type Cpr19). HPLC analysis of the reactions catalyzed by each of the
mutant variants revealed a either a peak identical to the product 1-[6’-Deoxy-6’phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil (5) as was previously observed for wildtype Cpr19, or a peak consistent with unutilized S11 if the corresponding point mutation
was responsible for abolishing substrate utilization in the mutant (Figure 3.3.3.1). These
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results were in agreement with the results with primary substrate UMP, with the
exception of C123A which recognized UMP as substrate but failed to do so with S11.
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Figure 3.3.3.1. Color coded HPLC traces for reactions catalyzed by Cpr19 mutants when
tested in reaction with substrate analog S11. Peaks corresponding to product 1-[6’Deoxy-6’-phosphono-β-D-ribo-(5’S)-hexofuranosyl]uracil (5) indicate recognition of S11
as a substrate by mutants S79A, W104A, H105A, T119A and C198A. Mutants C123A,
D107A and R260A, however, did not utilize S11 as a substrate. A260: absorbance at 260
nm.

3.3.4. Kinetic characterization of Cpr19 mutants with respect to substrate UMP
For single-substrate kinetic analyses involving the generated set of Cpr19 mutants, we
conducted reactions at 30°C at pH=7.5. Reactions were terminated after 3 min (<10%
product formation) by addition of EDTA, using a sample without enzyme as a
blank/control. Each data point represents triplicate end point assays. Kinetic constants
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were obtained by nonlinear regression analysis using GraphPad Prism (Figure 3.3.4.1).
The extracted kinetic constants are listed in Table 8.
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Figure 3.3.4.1. Single-substrate kinetic analysis of Cpr19 mutants with variable UMP at
pH=7.5: (a) W104A, (b) H105A, (c) C123A, (d) C198A.

Table 8. Kinetic constants for Cpr19 mutants
Enzyme
W104A
H105A
C123A
C198A

Substrate
UMP
UMP
UMP
UMP

kcat (min-1)
119 ± 18
2 ± 0.1
35 ± 1.38
65.35 ± 3.4

Km (μM)
51 ± 14
100 ± 25
19.87 ± 5
16.96 ± 6
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kcat / Km (μM-1min-1)
2.33
0.02
1.76
3.85

3.3.5. Enzymatic synthesis and spectroscopic characterization of structural substrate
analogues of UMP
The genes for nikR and uracil phosphopribosyl transferase (EcUpp) were cloned and
expressed in E. coli to yield soluble proteins with the expected sizes (Figure 3.3.5.1).
Previous HPLC analysis of the reactions catalyzed by both these enzymes when tested in
reaction with substrates xanthine and uric acid led to the identification of four different
products in our lab (unpublished data). HPLC analyses revealed the uptake of xanthine
and uric acid by both nikR and EcUpp, wherein it led to the observation of two distinct
product peaks in each reaction leading to predicted isomeric product pairs. A
representative HPLC trace is shown below (Figure 3.3.5.2 and unpublished data provided
by Dr. Van Lanen). Each of the peaks were collected from a semi-preparative C-18 HPLC
column and LC-MS was utilized for preliminary confirmation the identity of the products
(data not shown). In the present study, we provide NMR spectroscopic analyses of the
products further to discern the ‘connections’ in obtained products that were all
substrates analogs of UMP (differing in the ‘base’ component of the 5’-monophosphate)
(Figures 3.3.5.3- 6). Peaks are assigned to each product in the following tables (Tables 912).
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Figure 3.3.5.1. SDS-PAGE analysis of purified proteins (1) His6-NikR (expected 24.99 kD)
and (2) SDS-PAGE analysis of purified His6-EcUPP (expected 22.5 kD)

Figure 3.3.5.2. HPLC traces for the reaction catalyzed by NikR.
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Figure 3.3.5.3. 1H and 13C (500MHz, D2O) for xanthosine 5’-monophosphate (XMP).
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Table 9. Peak assignment for xanthosine 5’-monophosphate (XMP)
Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
5.76 (d, 1H)
4.54 (m, 1H)
4.36 (m, 1H)
4.21 (m, 1H)
3.96-3.94 (m, 2H)
----7.93 (s, 1H)

δH (J in Hz)
86.73
74.20
70.30
83.79
63.88
160.24
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Figure 3.3.5.4. 1H, 13C, 2D 1H – 13C gHSQC (500MHz, D2O) for substrate analog S2.
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Table 10. Peak assignment for substrate analog S2
δC, mult.
6.05 (d, 1H)
4.39 (m, 1H)
4.24 (m, 1H)
4.16 (m, 1H)
4.04-3.94 (m, 2H)
----8.19 (s, 1H)
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Figure 3.3.5.5. 1H, 13C, 2D 1H – 13C gHSQC (500MHz, D2O) for substrate analog S3.

Table 11. Peak assignment for substrate analog S3
Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
5.73 (d, 1H)
4.89 (m, 1H)
4.35 (app t, 1H)
4.13 (m, 1H)
3.81-3.69 (m, 2H)
------

δH (J in Hz)
85.66
70.95
70.66
85.32
61.74
154.97
148.86
97.61
152.78
158.19
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Figure 3.3.5.6. 1H, 13C, 2D 1H – 13C gHSQC (500MHz, D2O) for substrate analog S4.
116

0

Table 12. Peak assignment for substrate analog S4

Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
6.04 (d, 1H)
4.67 (m, 1H)
4.42 (app t, 1H)
4.2 (m, 1H)
4.10 (m, 2H)
------

δH (J in Hz)
89.11
71.45
69.57
83.31
64.38
163.24
127.59
109.95
150.27
172.44

3.3.6. In- vitro utilization of substrate analogs (XMP, S2, S3, S4) by LipL and Cpr19:
The previously synthesized substrate analogs (XMP, S2, S3 and S4) were tested in reaction
in vitro with both LipL and Cpr19, with the initial aim of probing substrate promiscuity for
both enzymes. HPLC traces obtained from these studies revealed product peaks
generated from all four substrate analogs by both LipL and Cpr19 (Figure 3.3.6.1). It is
important to note here that we conducted these reaction in HEPES buffer (as opposed to
Tris-HCl) since we did not want the predicted aldehyde products to be converted to their
corresponding tris-adducts. The generated product peaks were collected for subsequent
chromatographic analyses.
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Figure 3.3.6.1. HPLC analyses of reactions catalyzed by Cpr19 and LipL when tested with
substrate analogs XMP (A), S2 (B), S3 (C) and S4 (D). In all four chromatograms negative
controls are shown in black, while reactions catalyzed by LipL and Cpr19 are indicated in
green and blue respectively. In all four sets of reactions, the major peaks represent the
respective substrate peaks as labeled, and the product peaks (indicated in orange in each
set of reactions) were collected for further identification.
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3.3.7. Scale-up of product for NMR and mass spectroscopic analyses
Large scale isolation of the predicted aldehyde products starting from substrate analogs
(XMP, S2, S3 and S4) was carried out with HPLC using a C-18 reverse-phase semipreparative column using previously described iron-pairing conditions (flowrate of 3.5
mL/min). We selected the reaction with the highest yield of a product peak (starting from
S3) specifically to generate enough of the product to be able to gain both high resolution
mass spectrometric as well as 1H and 2D 1H-13C gHSQC NMR analyses (Figure 3.3.7.1,
Figure 3.3.7.2(c), Figure 3.3.7.3) . The innate instability of the aldehyde product limited
the scalability to obtain enough of the compound for assigning 13C spectra to the peaks.
Identity of the other three products were confirmed by high resolution mass
spectrometric analyses, since a low yield of product combined with the inherent
instability of aldehydes when subjected to column purification conditions made it difficult
to generate enough of the product for NMR analyses.

Figure 3.3.7.1. Projected net two-electron oxidation of substrate analog S3 to
corresponding 5’-aldehyde catalyzed by both LipL and Cpr19. This conversion would
imply flexibility of substrate recognition for both enzymes with respect to the ‘base’
component of its nucleotide substrate.
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Figure 3.3.7.2. HRMS analyses for product peaks collected from reactions starting from
XMP (A), S2 (B), S3 (C) and S4 (D). (A) HRMS (ESI+) calcd. for C10H10N4O6 [M + H]+
283.0634; found 283.0650; (B) HRMS (ESI+) calcd. for C10H10N4O6 [M + H]+ 283.0634;
found 283.0884; (C) HRMS (ESI+) calcd. for C10H10N4O7 [M + H]+ 298.0549; found
298.2392; (D) HRMS (ESI+) calcd. for C10H10N4O7 [M + H]+ 298.0549; found 298.0750.
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Figure 3.3.7.3. 1H, 2D 1H – 13C gHSQC (500MHz, D2O) for the predicted aldehyde product
from substrate analog S3.

Table 13. Peak assignment for proposed aldehyde product from S3

Position
1
2
3
4
5
6
7
8
9
10

δC, mult.
5.72 (d, 1H)
4.77 (m, 1H)
4.27 (app t, 1H)
4.08 (m, 1H)
7.67 (s, 1H)
------

δH (J in Hz)
85.99
64.13
63.55
78.12
135.84
Could not be assigned
Could not be assigned
Could not be assigned
Could not be assigned
Could not be assigned

3.3.8. Homology Modeling of Cpr19 and LipL structures
The predicted overall fold of Cpr19 is significantly similar to that of TauD, with ~25%
sequence identity. Interactions with Fe(II) in the catalytic center are proposed to involve
the residues His 105, Asp 107 and His 247 which form the facial triad, consistent with our
mutational studies. The predicted residues involved in stabilizing α-KG in the active site
are Thr 133 and Arg 260, based on alignment with TauD residues as well as our
observation of abolished enzyme activity with the Cpr19 R260A mutant (Figure 3.3.8.12).
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Figure 3.3.8.1: Comparison of the structures of TauD (on the left) and the predicted
structure for Cpr19 (on the right). The beta-strands of the conserved jellyroll motif are
colored in separately in red. Similarity of the core structures are visible, while the main
differences involve the extended loops over the active sites and helix in TauD (residues
160-182) that could not be modeled onto our structure. Substrates of each enzymes are
shown as sticks (α -KG, taurine and UMP) or the Fe(II) center is depicted as a sphere.

Figure 3.3.8.2. The predicted structure of Cpr19 (in blue) superimposed on the TauD
crystallographic structure (in green) indicates the regions that align smoothly, barring the
region extending from residues 160-182 in TauD.
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Primary substrate UMP (1) was docked onto the active site manually (Figure 3.3.8.3). As
an initial constraint, we superimposed the phosphate moiety of UMP with the analogous
sulfate moiety of taurine in TauD to position UMP in the active site. Since we showed in
the preceding chapter that Cpr19 selectively oxidizes the pro-S hydrogen of UMP, we
docked the substrate in a position so that this hydrogen would face the active site Fe(II)
center (Figure 3.3.8.4). In TauD, the amine of taurine is hydrogen bonded to Tyr 73, Asn
95 and Ser 158, whereas the sulfonate interacts with Arg 270, His 70 and the backbone
N-H of Val 102. While we could not implicate the residues that could be involved in
binding the uracil component of UMP, we could implicate Arg 264 (as the putative
equivalent of Arg 270 in TauD) for stabilizing the phosphate moiety of the substrate.

Figure 3.3.8.3. Overlay of the binding pocket of TauD (green) and Cpr19 (light blue). The
active site amino acids that are conserved between the two enzymes are shown in green
(TauD) and blue (Cpr19) (left). Docked UMP resides close to taurine in the TauD active
site, and its phosphate moeity has a conformation similar to the sulfate group in taurine.
Background ribbon shows surrounding protein structure (right).
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Figure 3.3.8.4. Docked UMP in the predicted active site of Cpr19. UMP was positioned
such that the pro-S hydrogen at C-5’ is directed towards the Fe(II) center (shown in
orange). Amino acid residues in the facial triad and co-substrate α-KG is additionally
depicted (Top). A 180o rotation of the same is viewed in the bottom panel.
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It is interesting to note here, in TauD the residues binding the amine part are less
conserved than the residues that bind the sulfonate component of substrate taurine.
Additionally, the amine component is relatively solvent exposed with a sizeable cavity
adjacent to its position which confers relative substrate flexibility to TauD wherein it has
been shown to accommodate alternative larger sulfonate substrates such as 3-(Nmorpholino)propanesulfonic acid (MOPS) [69], which can be understood in relation to the
available substrate-binding cavity and presumably the higher importance of the
sulfonate-binding ligands over those binding the amine group of taurine. In our predicted
Cpr19 model, we observe a similar cavity where the uracil component of UMP was
docked. We borrow on this logic to dock the alternative substrates that were shown to
be recognized as substrates (as well as being converted to their corresponding 5’aldehydes), by both Cpr19 and LipL in the preceding sections. We aligned the
monophosphate moieties of each of these substrates with the taurine sulfonate group to
arrive at predictive active site positions for each of these substrates as shown in Figures
3.3.8.5-6.
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Figure 3.3.8.5. Docked XMP in the predicted active site. XMP (in red) overlaps primary
substrate UMP (shown in pink), which in turn resides close to taurine (in rainbow colors)
in the active site. Amino acid residues involved in the facial triad are depicted as sticks
that interact with the Fe(II) center in the background.

Figure 3.3.8.6. Docking all four substrate analogs into Cpr19 model. All four substrate
analogs (XMP, S2, S3 and S4) are docked to overlap primary substrate UMP (shown in
pink), docked onto the active site. The predicted Cpr19 model can accommodate these
relatively larger substrate analogs in a proposed cavity adjacent to the position of the
taurine amine in TauD.
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Analyses of the other mutated residues that did not abolish the activity of Cpr19 in the
predicted structure established that they are not directly involved in the active site
binding pocket or in stabilizing the substrates. One of the cysteine residues (Cys 198)
resides on a loop (Figure 3.3.8.7) and could by hypothesized to be involved in dimer
formation. A native PAGE of Cpr19 (data not shown) adds weight to this hypothesis
wherein we observed protein bands additional to the monomer band, which could
theoretically correspond to a functional dimer or other polymeric chains of Cpr19. Both
C198A and W104A mutants had higher activities than the wild type Cpr19 (Table 8), which
could be indicative of indirect of indirect influences of both these residues on substrate
access to the active site of the enzyme. Especially with reference to the Trp 104 residue,
this could be a plausible explanation since it is located adjacent to His 105 and Asp 107,
which are involved in forming the facial catalytic triad that coordinate the Fe(II) in the
catalytic center.

130

Thr 119

Cys 198

Figure 3.3.8.7. Mutated residues in Cpr19 model. Mutated residue Cys 198 is located on
a loop and could be theorized to take part in disulfide formation in chain polymerization.
Residue Thr 199 is located on one of the β-strands that constitute the jellyroll fold of
Cpr19.

For developing the LipL model, the previously predicted Cpr19 homology model was used
as a template given the high degree of homology between LipL and Cpr19. We then
inserted Fe(II) and co-substrate α-KG using PyMOL onto the predicted LipL active site,
resulting in nearly perfect alignment of the active site residues as expected (Figures
3.3.8.8-9).
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Figure 3.3.8.8. The predicted homology model of LipL. Predicted LipL structure (in blue)
superimposed on the Cpr19 model (in red) indicates the regions that align smoothly, with
minor differences in the extended regions with loops. Cosubstrate α-KG and Fe(II) are
modeled onto the predicted active site.

Figure 3.3.8.9. Overlay of the binding pocket of Cpr19 and LipL. Cpr19 residues (green)
and LipL residues (light blue) are aligned to show conserved regions.
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3.4.

Conclusion

In summary, we have identified the amino acid residues His 104, Asp 107 and His 247 as
the key residues involved in forming the 2His-1 carboxylate facial triad in Cpr19 via a
combination of bioinformatics analyses, mutational and computational studies. By using
TauD as a template, we first identified residues that were conserved with Cpr19 and LipL.
This afforded us the platform to target certain residues in Cpr19 that could potentially be
implicated in playing vital roles in enzyme catalysis. Initial hypothesis for a tandem
phosphatase/oxidoreductase mechanism for Cpr19 (and LipL) led to the identification of
the cysteine residues (Cys 123 and Cys 198) as plausible sites for a phosphatase type
mechanism. However, characterization of the enzymes as dioxygenases, accompanied by
the results from mutating these residues effectively negated the phosphatase hypothesis.
Abolishment of activity in the Cpr19 R260A mutant as well as its alignment with the
equivalent Arg 266 in TauD helped to establish its role in stabilizing co-substrate α-KG in
the active site. Prediction and alignment of the Cpr19 model utilizing TauD
crystallographic structure as a template furnished two more conserved residues: Thr 133,
which is proposed to interact with α-KG, and Arg 264 which could be involved in stabilizing
the phosphate moiety of UMP. Prime substrate UMP, as well as substrate analogs XMP,
S2, S3 and S4 were docked into the predicted active site drawing on combinatory chemical
logic and alignment with taurine sulfate moiety. A predictive model for LipL was also
generated by using the predicted Cpr19 as a template.
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3.5.

Discussion

Enzymes belonging to the Fe(II): α-KG dependent superfamily are some of the most
versatile enzymes that can stereoselectively activate alkyl C-H bonds in a variety of
substrates resulting in many pivotal metabolic transformations. Despite the broad
spectrum of distinct transformations catalyzed by these enzymes, crystal structures of a
number of different members from this group show a conserved double-stranded β-helix
(or jellyroll) as a common architecture for this superfamily . The highly conserved His1-XAsp/Glu-Xn-His2 motif (facial triad) constitutes the facial metal-binding ligands that binds
the high-spin Fe(II) center. Sequence analyses of members in this group reveals little
overall similarity, leading to the proposal that convergent evolution to a common
mechanism and active site chemistry occurred within the wider family of Fe(II)/ α-KG
dependent and related oxygenases.

While a significant number of enzymes from this superfamily have been crystallized, the
enzyme TauD has proven to be the most suitable model for the dioxygenases LipL and
Cpr19 characterized in our lab, given the high degree of structural similarities between
primary substrates taurine and UMP. In the absence of crystallographic structures of
these enzymes, we have designed mutational variants of Cpr19 aimed at identifying key
amino acid residues that impact enzyme activity. Either retention or abolishment of
enzyme activity in individual mutants helped in establishing proposed roles for some of
these residues in influencing catalysis. An in-silico model of Cpr19 was generated as an
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attempt to locate these residues in the predicted enzyme structure. We assimilated the
information gathered from the mutational studies with the obtained model to assign
theoretical roles to a few more residues based on the model. Additionally, we docked the
primary substrate UMP based on its alignment with taurine in the TauD active site,
incorporating our observation from the preceding sections that the pro-S hydrogen at C5’ of UMP is preferentially abstracted. While these studies are purely theoretical, we
believe we have obtained a suitable model for Cpr19 and LipL to further build upon, while
parallel efforts to crystallize the enzymes are ongoing in our lab. We have had limited
success with LipL, wherein 5Å resolution crystals were obtained from a high throughput
screening (Figure 3.5.1). However, this resolution is too high to be able to visualize its
tertiary structure accurately.

Figure 3.5.1. Crystals of LipL obtained from high throughput screens
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Chapter four: Summary
MraY (translocase I) is one of the twelve ubiquitous enzymes involved in peptidoglycan
biosynthesis, and viable target for targeting and antibiotic development. Of the several
classes of nucleoside inhibitors, we emphasize on the pathways leading to the
liposidomycins and capuramycins, and more specifically on the enzymes responsible for
initiating these pathways. The dioxygenases LipL and Cpr19 were both characterized as
members of an intriguing and diverse superfamily of Fe(II)/α-KG dependent enzymes and
shown to possess the capability to utilize UMP as the starting precursor for high-carbon
nucleoside biosynthesis. In this thesis, we delve into the mechanistic details of these
enzyme machineries, highlighting the unique reaction coordinates of both these enzymes
by overcoming the limitations of its proposed radical-mediated kinetics. By engineering
substrate analogs for specific purposes (deuterium labeled UMP and chemically
synthesized phosphonate analog) we provide distinctive methodologies to be able to
differentiate between a ‘hydroxylation’ versus ‘desaturation’ hypothesis, establishing
that the enzyme in fact hydroxylates UMP at C-5’ and it does so by first preferentially
abstracting the pro-S hydrogen from this position. This key observation was used down
the line to obtain an in-silico model for Cpr19 with UMP docked onto its catalytic pocket.
We additionally explored, and unexpectedly discovered substrate promiscuity of both
enzymes resulting in novel products, which in theory can be further utilized to generate
novel scaffolds from these (and related) pathways. Ongoing efforts to crystallize both
enzymes would hopefully lend weight to our hypothesized models, and once completed
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would afford the opportunity to engineer related enzymes from other strains as well to
generate analogs by combinatorial biosynthesis.
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